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Summary
In Tanzania, the National AIDS Control Program with the support
of Non-Government Organizations is scaling-up Antiretroviral
Therapy (ART) services to peripheral (rural) health facilities. The
aim of scaling-up is to improve availability, access and adherence
to ART by all HIV-infected population.
HIV-infected persons in peripheral (rural) areas are at increased
risk for several medical co-morbidities including tuberculosis,
bacterial and parasitic infections. As ART is successfully made
universally available, non-AIDS co-morbidities caused by
helminths and malaria will emerge as leading problems that will
complicate care, adherence to ART and retention. These
challenges can be improved by comprehensive and
multidisciplinary management strategies. In addition a range of
interventions such as counselling, use of treatment assist ants
and integrated health services delivery need to be enhanced to
improve adherence and treatment of co-morbidities.
However, concerns are raised regarding proper HIV/AIDS
management in the peripheral (rural) settings which focuses on
clinical monitoring and treatment of opportunistic infections.
Clinical monitoring is based on WHO clinical st ages and CD4+
T-lymphocyte counts. Clinicians in the peripheral (rural) settings
faces challenges in accessing CD4+ T-lymphocyte counts, HIV
and AIDS clinical features not corresponding with WHO clinical
stages, co-infections and co-morbidity.
The aim of the work reported in this thesis was to conduct
research to investigate effects of concurrent parasites infections
and challenges of HIV/AIDS case management on peripheral
(rural) patients in order to contribute information towards better
care for HIV/AIDS patients in Tanzania.
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The studies were conducted at Tumbi Hospital and Chalinze
Health Centre in Tanzania between April 2008 and June 2009.
The research consisted of three sub-studies carried out
consecutively utilizing different study designs and populations.
The first study examined the ef fects of parasite co-infection on
CD4+ T-lymphocyte counts, WHO clinical st aging and
haemoglobin. In addition, the study attempted to develop a
simplified clinical staging by utilizing local experiences HIV/AIDS
clinical manifestation. Adult patients registering for the first time
at HIV-clinic were clinically examined for malaria parasites and
helminths. CD4 counts and haemoglobin were also analyzed.
Patients were initiated on treatments according to their respective
diagnosis and followed up for six months. At 6 months, clinical
procedures were performed similar to first contact assessment.
The second study utilized a case-control design to elucidate
factors associated with non-adherence to ART. Adult patients
attending care and treatment at the study clinics and being on
ART for at least three months were studied. Patient s with ART
adherence of less than 95%; and those with more than 95%
were defined as cases and controls respectively.
The third study was an observation study which documented
experiences and lessons generated in the process of
implementing ART services at Chalinze health centre. Clinical
procedures were evaluated and document review was carried
out to solicit patients’ characteristics and enrolment rates.
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Main findings
Of the 421 HIV -1 infected p atients studied for p arasites co-
infection, 198 (47%) were co-infected with one or more parasites.
While 93/421(22.1%) patients had helminths only co-infection,
and 50/421(12.9%) had Plasmodium sp only co-infection. The
most frequently helminths diagnosed included hookworm 65/
421(15.4%), Schistosomiasis 49/421(11.6%), Strongyloides
stercoralis 57/421(13.5%), and  Ascaris lumbricoides 54/
421(12.8%). There was no statistical associations between CD4+
T-lymphocyte counts <200/µl, or WHO clinical st age III/IV with
parasites co-infections (AOR 1.2, 95%CI 0.8-1.8).
Anaemia was common in p arasite co-infected patients (32.5%
vs. 18.8%). Parasites co-infection was associated with risk of
anaemia (AOR 2.1, 95%CI 1.3-3.2). In multivariable logistic
regression analysis, baseline CD4+T cells <200/µl was
significantly (AOR 2.4, 95%CI 1.3-4.7) associated with
CD4+Tcells <200/µl at six months. HIV -1 P24 antigen mean
concentration was higher in parasites co-infected patients (ranges
47.6 to 56.9pg/µl) comp ared to patients without parasites co-
infection (5.5pg/µl).
HIV/AIDS clinical presentation showed that weight loss was the
commonest symptom (48.3%); followed by chronic cough
(40.8%). Most symptoms were found to be highly specific (ranging
from 56.4% to 98.6%) with high positive predictive values (ranging
from 57.9% to 80%) in predicting severe immunosuppression
using CD4d”350 as ‘Gold standard’. Chronic diarrhoea presented
in 10.6% of p atients, and predicted well severe
immunosuppression alone or in combination of symptoms (with
high likelihood ratios ranging from 1.83 to 3.27 at 95%CI).
Headache, skin and fungal diseases presented highly but
relatively weak in predicting immunosuppression.
The combination of 3 symptoms correlated with the WHO stages
III/IV with high specificity and positive predictive values, but had
xv
lower sensitivity. The sensitivity of all the presenting symptoms
remained lower than 52%, and was not improved by including
more signs and symptoms in the analysis.
In the evaluation of factors related to non adherence to ART, a
total of 79 cases (non adherence) and 237 controls (adherent)
matched by age and sex were studied. A high proportion of cases
and controls (77.2% and 84.8%) had good knowledge of ART
benefits, adherence and eligibility. Majority of cases (73.3%) and
controls (69.2%) used public transport to access ART services.
In the univariate analysis: missed clinic appointments due to lack
of fare or other reasons and was associated with ART non
adherence (mOR 4.2, 95%CI, 2.2-8.1 and 2.1, 95%CI 1.2-4.2,
respectively).  Disclosure to confidants only and failure to disclose
HIV-test positive status were associated with non adherence
(mOR 3.3, 95%CI 1.3-8.5 and 2.3, 95%CI 1.2-7.1, respectively).
Alcohol use was associated (mOR 1.9, 95%CI 1.4-3.7) with non
adherence to ART. Patients who were not satisfied with providers
were more likely to be non adherence to ART (mOR 2.0, 95%CI
1.2-3.8). In the multivariate analysis same factors were found to
be associated with no adherence to ART.
The study at Chalinze health centre showed that, 611 care and
284 ART patients were attended between May 2007 and June
2009. Majority of p atients 762/895 (85.1%) were adult s aged
25-45 years, while children were 27/611 (4.4%) pre ART and 16/
284 (5.6%) ART. In total 550/895 (61.5%) patients had CD4+T
lymphocytes d”350/µl the cut-of f point for initiating ART. The
frequency of symptoms was noted to significantly decrease with
increasing CD4 counts (p<0.001).
In conclusion, we have looked at one set of parasites and found
high prevalence of malaria and helminths co-infection in HIV -
infected individuals. Based on local helminths epidemiology and
HIV-infected cohort specific helminths co-infection prevalence
data, mass treatment of soil transmitted helminths can be
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confidently incorporated in HIV/AIDS care and treatment
programs.
HIV/AIDS clinics managing large cohort s should review and
validate site specific HIV clinical manifest ations in comparison
with CD4 count s and WHO clinical st ages. Based on local
experiences simplified guidelines are useful for resource
constrained settings without CD4 counting facilities.
These findings show that adherence is a dynamic process that
varies depending on region or cohort specific adherence factors.
Adherence improvement strategies need to consider site specific
adherence determinants, patient experiences and concerns.
ART services can successively be provided at health centre level
and encourages HIV-infected persons to seek care. However ,
clinicians need regular clinical mentorship and supportive
supervision.
1Part I
Introduction
2
3Chapter 1: Emergence and Evolution of HIV and AIDS
1.1 Global Burden of HIV/AIDS
In 2009, UNAIDS and WHO published data showing that there
are 33.4 million people living with HIV/AIDS globally. Sub-
Saharan Africa is the most affected region with 22.4 million people
living with HIV/AIDS. During the same period 2.7 million people
became infected with the human immunodeficiency virus (HIV),
1.9 million from sub-Saharan Africa and 2.0 million deaths were
accounted for by AIDS worldwide while 1.4 million deaths
occurred in sub-Saharan Africa. The prevalence of HIV varies
considerably across sub-Saharan Africa ranging from less than
1% in Niger to over 25% in Swaziland. About two thirds of infection
is through men to women sex (1) (2). Women account for
approximately 60% of people living with HIV/AIDS (1).
1.2 History and epidemiology of HIV
The origin of the global HIV-pandemic is difficult to determine
and when and where the first cases of AIDS and or HIV infection
occurred are still unknown. However, retrospective studies in
central Africa reported on the epidemic increases of clinical
diseases markers of AIDS in the late 1970’s and early 1980’s. In
addition, HIV was later identified in blood samples collected from
central Africa which pointed to the earlier occurrence of HIV
infection in central African countries.
The first reported AIDS cases were defined in young homosexual
men in United States of America in 1981, who presented with
aggressive Kaposi’s sarcoma and Pneumocystis carinii
pneumonia (3)(4)(5). During the same period, new cases of fatal
wasting disease were described in sub-Saharan Africa in
heterosexual men and women (6). Subsequently epidemiologic
and virologic investigations identified the cause of AIDS as
Human Immunodeficiency Virus (HIV) (7)(8).
4The route of HIV transmission was described few years later
following observational studies in Europe, sub-Saharan Africa
and America (9)[(10)(11). Although the disease affected different
groups of the population in each of the three continents, it become
apparent that HIV was transmitted through heterosexual and
homosexual contact; infected blood transfusion; intravenous drug
use by sharing needles, therapeutic practices and vertical
transmission from mother to child (MTCT)(11)(10)(12). In sub-
Saharan Africa, HIV transmission is largely through heterosexual
contact in adults, but also through MTCT and therapeutic
practices.
During the early years of the epidemic it became clear that HIV/
AIDS was already spread worldwide killing young adults (15-49
years). Sub-Saharan Africa was severely affected, harbouring
two thirds of the global total numbers of HIV (13). Within the first
decade of the pandemic, sub-Saharan Africa experienced a
generalized epidemic and was hit hard by the disease. Many
countries of the region reached HIV prevalence of 10% to 40%
(14).
Socio-cultural, civil unrest in the great lakes and economic factors
facilitated the quick spread of HIV in sub-Saharan Africa region
(15). Wide spread poverty, and cultural practices that encouraged
inheritance of widows and ritual cleansing played a substantial
role in HIV transmission (16) (17). Poverty forces young women
to engage into commercial sex; while young men migrate to urban
centres as traders and casual manual workers. These economic
activities exposed both young men and women to high risk sex
behaviour. The presence of behavioural factors and the biologic
influence of Sexually Transmitted Diseases (STD) facilitated rapid
transmission of HIV (18).
51.3 Global HIV prevention methods
After recognition of the major routes of HIV-infection, prevention
measures were designed and instituted globally. HIVIAIDS
awareness creation through mass education campaigns using
public media; and declaration of one’s HIV-positive status in
public; especially that of celebrities, created awareness of the
disease and helped to draw attention of the international
community (19). Abstinence; be faithful to one partner; and use
of Condom (ABC) were introduced and still are key measures to
curtail further spread of the disease (20). Male and female
condoms provide a proven and affordable prevention option (21).
Other measures include prevention of mother to child HIV
transmission (PMTCT) by use of Nevirapine, AZT or combination
therapy (22). Blood screening for HIV and Syphilis before
transfusion; and voluntary counselling and testing (VCT) are
important interventions undertaken to prevent HIV infection.
Needle exchange programs were introduced as part of the
prevention methods for Intravenous Drug Use (IDU) (23).
Recently, additional prevention measures include male
circumcision, vaginal microbicides and use of antiretroviral in
post-exposure prophylaxis (24) (25). Male circumcision has been
endorsed by the World Health Organization as one of the
preventive measures after results of multi-country clinical trials
conducted in Kenya, Uganda and South Africa (26). Vaginal
microbicides the only prevention method that can be controlled
by women have been waited for more than two decades.
Recently, a South Africa clinical trial produced results on vaginal
microbicides containing tenofovir gel which provided efficacious
protection against HIV-1 transmission in women (27).  It is the
first time for a biological intervention against HIV-1 to be very
successful with high level of efficacy. HIV-1 vaccines as
prevention methods are under development (28), and several
candidates are at various stages of development (29). The
existence of different HIV-1 sub-types and the continuous
6mutation of the virus posses a great challenge to development
of universal vaccine. In sub-Saharan African region alone there
is more than 5 different sub-types genetically distinct HIV-1
isolates (30) (31).
Successful implementation of the fore mentioned measures
depends heavily on a country’s political will, economical
development and readiness to acknowledge HIV as a human
disaster and availability of international community support (32).
Uganda and Senegal represent two success stories in sub-
Saharan Africa. Uganda has brought estimated prevalence rate
down to 5% by the end of 2001 from an estimated peak of close
to 14% in the early 1990s with strong prevention campaigns (20).
HIV prevalence has stabilized in Senegal at a relatively low level
(30). Uganda responded much earlier to the epidemic than
Tanzania.  Tanzania government acknowledged HIV/AIDS as a
human catastrophe in 1999 almost two decades after the first
case was described in Kagera Region (33).
1.4 HIV and AIDS care and treatment
In 1986, dramatic progress in the medical treatment of AIDS
was made by the introduction of azidothymidine or Zidovudine
(AZT), an anticancer drug that was effective at slowing down the
HIV virus (34). The U.S Food and Drug Administration approved
the use of dideoxycytidine (ddC) in combination with AZT for
adult patients with advanced HIV infection who were continuing
to show signs of clinical or immunological deterioration. This was
the first successful use of combination drug therapy for the
treatment of AIDS. More drugs were gradually introduced into
medical practice, including Lamivudine (3TC), Nevirapine and
others (35) .
Successive use of combination antiretroviral therapy and the
improvement in health of those had been ill in hospitals in the
USA, created hopes of a complete cure. The approach to
7treatment was described as “hit early, hit hard”, starting ART
with the goal of virologic suppression and eliminate all reservoirs.
It was learnt that aggressive treatment with multiple drugs can
convert deadly AIDS into chronic, manageable disorder like
diabetes. Important issues of drug toxicity, resistance and
adherence became considerations (36).
Currently, there are more than 19 antiretroviral drugs approved
for the treatment of HIV infection, in 3 mechanistic classes (37)
(31): HIV reverse transcriptase inhibitors, HIV protease inhibitors
and HIV entry inhibitors. Nucleoside Reverse Transcriptase
Inhibitors (NRTIs): the primary mechanism of action of this class
is inhibition of viral RNA-dependent DNA polymerase (reverse
transcriptase) enzyme. Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTIs) unlike the NRTIs, they are not directly
incorporated into the viral DNA but instead inhibit replication
directly by bind-ing to the enzyme reverse transcriptase.
Resistance to these drugs develops rapidly, especial-ly when
used alone. Protease Inhibitors (PIs) competitively inhibit the
HIV protease enzyme whose activity is critical for the terminal
maturation of infectious virions (37) (31). This inhibition prevents
the maturation of virions capable of infecting other cells. HIV
entry inhibitors include CCR5 inhibitors and integrase strand
transfer inhibitor (37).
1.4.1 HIV and AIDS current case management
Until 2004, because of high cost and complexity of administering
ARVs, drugs were mostly limited to treating HIV-infected patients
in the developed world (38). Due to global initiatives the prices
of antiretroviral drugs have fallen sharply, treatment is becoming
widely available and is provided free in developing countries.
HIV case management is different between developed and
developing countries due to variable resources availability. Patient
assessment, monitoring and treatment in developed countries
involve a range of complex laboratory testing and many drug
8regimes as compared to developing countries. For example in
USA, drug resistance testing before initiation of therapy and use
of CCR5 inhibitors (Maraviroc) which are expensive undertaking
in developing countries. WHO developed guidelines for ART to
be used in resource limited countries and is adapted to country
specific conditions (39). But still there is variability in HIV case
management in resource limited countries between central and
peripheral (rural) clinics due to uneven resources allocation which
tend to favour the central clinics.
1.4.2 Patients’ entry to HIV and AIDS care and treatment
Patients are identified after a HIV-positive antibody test from:
voluntary counselling and testing units (VCT); PMTCT at RCH
services and Provider Initiated Testing and Counselling (PITC)
in medical wards and outpatient clinics; tuberculosis clinic;
sexually transmitted Infection (STI) clinic. HIV-1 infection can be
diagnosed by detection of specific antigens (DNA PCR in infants
and children<2years), antibodies or both from plasma, whole
blood, serum, or saliva.  Health care workers provide rapid HIV
tests (A sequence of two tests) and confirmatory tests may be
performed by using ELISA test or Western blot (where available)
in laboratory (40). Before the test is performed; the patient is
taken through a session of counselling and HIV education in a
group or one by one counselling depending on the setting [(41).
Then, the patient has the option of accepting the test (Opt-out).
After confirmation of the HIV-positive status the patient is referred
to the Care and treatment clinic for continuous management
and monitoring.
1.4.3 Initiation of antiretroviral therapy
The initial assessment of a HIV patient includes clinical and
laboratory evaluation (42). Then, the patient clinical disease is
classified according to WHO clinical disease staging criteria (43):
Stage 1- Asymptomatic; Stage 2-Mild disease; Stage 3-Advanced
disease; and Stage 4-Severe disease. In places where laboratory
9investigation are not available; Patients with WHO clinical stage
3 or 4 are eligible for starting ARVs treatment.
Laboratory investigation such as haematology, chemistry and
CD4 cell counts are done to provide addition information and
treatment monitoring.  ARV treatment is better commenced after
a combination of clinical and immunological staging. Although
there are addition considerations but a patient with CD4d”350
cells/mm3 is eligible to start ART regardless of clinical stage.
Previous guidelines considered the cut-off point of CD4d”200
cells/mm3 as a threshold at which the body can still mount
immune response and below which the risk of Opportunistic
Infection increases.  Patients with HIV and tuberculosis co-
infection regardless of CD4 cell count levels and pregnant women
with CD4d” 350 cells/mm3 are eligible for ART. ART is not
indicated for patients with CD4>350cells/mm3. Beyond clinical
eligibility, it is important that the patient’s willingness, readiness
and ability to be on ART adherently be assessed and addressed.
The patient is made to understand that ART is a lifelong treatment;
and the importance of adherence to treatment and common drug
toxicities (39).
The best time point to start ART treatment to asymptomatic
patients with CD4>350cells/mm3; and modest levels of viraemia
(less than 100,000 copies per ml); remains controversial (40)
(36). Early depletion of gut CD4 lymphocytes, increasing viral
diversity and the poor generation abilities of key populations of
the immune system provide arguments for beginning treatment
as early as possible. Additional considerations include long-term
drug toxicities; treatment costs and immune reconstitution
disease are some of the complications of long term HAART (41).
Cotrimoxazole prophylaxis is recommended to all HIV infected
patients with CD4<350 cells/mm3 or clinical stages 2, 3 and 4
including pregnant women in resource limited settings. Clinical
trials have showed consistent benefit of Cotrimoxazole
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prophylaxis in the reduction of morbidity and mortality among
people living with HIV with varying CD4 counts with and without
Mycobacterium tuberculosis (44).
The recommended criteria to start ART confer benefit to patients
on continuous clinical monitoring identified prior to profound
immunosuppression. Studies have shown that patients
presenting with pre ART of CD4<50cells/mm3, have a greater
risk of death soon after starting ART (45). Several factors may
account to this high risk of mortality: at a lower CD4 cell count
severe opportunistic infection occurs including disseminated
Tuberculosis (46); Immune reconstitution inflammatory syndrome
tend to occur more frequent in patients with lowest CD4 cells.
Patients in resource limited settings usually are identified late in
the disease progression with CD4<200cells/mm3 or clinical stage
4. ART-LINC collaboration recoded 4% mortality rate in the first
six months which dropped to 2% in the next 6 months of active
patients follow up. The early deaths were attributed to advanced
disease (47).
1.4.4 Antiretroviral therapy
The standard of care for treatment of HIV infection has evolved
from the use of single-drug therapy, to dual-nucleoside analogue
therapy to the current standard of care, 3-drug therapy with 2
nucleoside analogues in combination with a non-nucleoside
reverse transcriptase inhibitor or a protease inhibitor. First line
ARV combination regimen for adults and adolescent ART naive
patients recommended by the WHO for use in resource limited
settings includes (39):
I. Stavudine (d4T) +Lamivudine (3TC) or Emtricitabine (FTC)
+Nevirapine (NVP
II. Zidovudine (AZT) +Lamivudine (3TC) or Emtricitabine (FTC)
+Nevirapine (NVP)
III. Stavudine (d4T) +Lamivudine (3TC) or Emtricitabine
(FTC)+Efavirenz (EFV)
IV. Zidovudine (AZT) +Lamivudine (3TC) or Emtricitabine (FTC)
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+ Efavirenz (EFV)
V. Tenofovir (TDF) +Lamivudine (3TC) or Emtricitabine (FTC) +
Efavirenz (EFV) or Nevirapine (NVP
Second line ARV combinations include:
I. Tenofovir (TDF) +Lamivudine (3TC) or Emtricitabine (FTC) +
atazanavir (ATV) with boost ritonavir or lopinavir/ritonavir
II. Zidovudine (AZT) +Lamivudine (3TC) +atazanavir (ATV) with
boost ritonavir or lopinavir/ritonavir
These combinations were formulated considering less drug
toxicity, simplification of administration, less antagonism and few
chances of early development of viral mutations (41). Common
early and potentially severe toxicities are hypersensitivity to
NNRTIs (EFV and NVP) occurring within the few weeks of therapy
(48). Others include AZT-related anaemia and neutropenia
presenting within few months after initiation of therapy (49).
Stavudine causes long-term toxicities e.g. lipoatrophy and
peripheral neuropathy; Stavudine is no longer in use in USA and
Europe and is been phased out in resource limited settings (42).
It is still in use in developing countries for reasons of cost and
availability.  Hepatic, renal and lactic acidosis drug toxicities
require laboratory tests to be identified. Common ARV toxicities
can be summarized in the following groups: Haematological
toxicity most seen with AZT(50); Mitochondrial dysfunction seen
with NRTI drugs; Renal toxicity seen with IDV and TDF; Allergic
reactions caused by NNRTI and sometimes NRTI, ABC and some
PIs; other metabolic abnormalities are more common with
Protease Inhibitors (51) .
1.4.5 Clinical and laboratory monitoring of patients on ART
Ideal patient and ARVs drugs monitoring involve: clinical
progression; immunological; viral load measurement; and drug
resistance monitoring. Drug resistance monitoring testing (by use
of both genotyping and phenotyping); viral load (HIV RNA levels)
measurement; and CD4 T-lymphocytes cell count in adults and
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CD4% in infants are part of the routine standard care in developed
countries(39).
In most sub Saharan countries patient monitoring is limited to:
Clinical progression based on WHO disease stages and limited
laboratory tests. Laboratory tests performed include
haematological, biochemistry and CD4+ T-lymphocyte counts.
Each patient should have at least these tests done at baseline
before initiating treatment. CD4+ T-lymphocyte count can then
be repeated at least every 6 months. Monthly assessment of
haematological and biochemistry parameters are performed to
assess drug toxicities. ELISA assay of HIV-1 P24 antigen in plasma
is another method that can be used to monitor patients on ART
in places where viral load is not available (52). P24 ELISA assay
is relative less expensive compared to viral load measurements,
thus can be adopted for use in rural district hospitals.
However, these methods and parameters cannot be used to
monitor patients in peripheral (rural) health centres due to lack
of qualified staff and laboratory equipments. Only district and
referral hospitals can perform these tests. Again, routine daily
shipping of samples from rural health centres to district
laboratories is challenged by logistic issues like transport
problems and costs. It is therefore important to research the
minimum essential laboratory requirements that can be used to
monitor HIV patients in rural settings.
Good clinical progression is assessed by determination of weight
gain and reduced morbidity from opportunistic infections; and
improvement in patient’s quality of life. Appearance or persisting
opportunistic infections, or lack of weight gain, may indicate
treatment failure and so the need to consider changing regimens.
Treatment is to be considered successful if the viral load
decreases by 1 to 2 logs (10 to 100 folds) from the baseline
level. However in most cases, CD4+ T-lymphocyte count will be
used instead of viral load thus a rise in CD4+ T-lymphocyte count
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will indicate success. Treatment failure on the other hand is
indicated by a viral load increase of 0.3 to 0.5 logs or a 30% fall
in CD4+ T-lymphocyte count (39).
1.4.6 Treatment failure
The introduction of HAART worldwide improved the trends of
HIV/AIDS morbidity and mortality even in developing countries
(53). Patients can now survive longer than before HAART (54)
(55). Great efforts of the international community have been
employed to assist developing countries, especially sub Saharan
Africa to fight AIDS. The combined efforts resulted in better
understanding of the dynamics of the epidemic. Universal access
to care and treatment through the UNAIDS “3by5” agenda is
achieving success in making ARVs available to the poor
communities in countries like Tanzania (43).
However, treatment failure causes a considerable challenge to
both patients and providers. Currently, there is no standard
definition of treatment failure. The WHO defines treatment failure
in three groups of clinical failure, immunological failure (based
on CD4 cell count) and virological failure. Clinical failure is
considered when there is new or recurrent WHO stage 4
conditions (with exemptions) (39). Immunological failure is
defined as fall of CD4 cell count to pre-therapy baseline (or
below); or 50% fall from the on-treatment peak value; or persistent
CD4 levels below 100cells/mm3. Virological failure is considered
when plasma viral load is greater than 103 copies/ml. Several
other clinical and immunological issues need to be considered
before deciding existence of treatment failure. While virological
failure is inability to achieve an undetectable HIV-RNA
(<50copies/ml) after six months of HAART or sustained rise of
HIV-RNA of >50copies/ml or >400 copies/ml following
suppression below this level (56).
There are a number of causes of treatment failure which include:
HIV virus mutation; baseline patient characteristics; baseline drug
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resistance; suboptimal adherence (57); drug side effects and
toxicity; pharmacokinetic issues; and other reasons specific to
individual patients. In the Swiss and Hopkins HIV Cohort Studies,
some of the factors which were associated with higher risk for
virologic failure included lower CD4 cell count and symptomatic
HIV disease at presentation prior to ART and missed clinic
appointments (58). In addition suboptimal adherence to ART is
associated with treatment failure. These reasons are common
in rural limited resource settings in Tanzania (59).
1.4.7 Access, Availability and Adherence to ART
Access to ART is a major challenge in sub-Saharan Africa due
to limited resources and the high burden of HIV and AIDS. At the
end of 2008, the estimated coverage of ART in this region was
44% (60). Despite this encouraging progress, the majority of
patients in need of ART in peripheral (rural) areas still are unable
to access treatment given the distances from ART clinics. The
few patients that access ART cannot sustain regular monthly
follow-ups and often drop out of treatment. In recent years,
considerable energy and money have been spent trying to
achieve universal access to treatment for HIV and AIDS. Such
efforts have generated replicable experiences regarding provision
of ART in peripheral (rural) settings. The extraordinary chronic
disease clinic at Saint Francis Designated District Hospital at
Ifakara is one of the few peripheral based programs reaching
the poor patients in need of ART (61). This program highlights
major issues in the process of scaling-up ART in resource limited
peripheral settings: first is the need for a functional patient referral
system; secondly uninterrupted supply of ART. Stock out of ART
is critical in these remote (peripheral) areas where patients cannot
afford return multiple clinic visits. The third lesson learned is the
use of treatment assistants, who support the patient to access
and adhere to ART.
Non adherence to therapy is a major cause of drug resistance. It
might be inevitable after prolonged periods of ARV use to develop
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resistance. However, the major interest is to delay drug resistance
development because there are limited available drug regimens
options. A patient is expected to achieve more than 95% of
adherence to protect resistance viral strain development (62).
This level of adherence is challenging in resource constrained
settings. Social and economic factors impact on the patients’
capacity to achieve adequate adherence (63). Provision of free
antiretroviral therapy and promotion of social coping may
enhance adherence and reduce possibility of development of
drug resistance (59). Stigma, poverty and distance from the care
and treatment centres are some of the socio-economic barriers
to adequate adherence to therapy. Other factors found to be
associated with drug resistance development include lower CD4
cell of <200 cells/µl, and the missing of a scheduled clinic visit in
the past month (64). These factors are frequently found in
resource limited countries. Population socio-economic diversities,
antiviral drug resistance and the HIV virus dynamics need to be
closely studied.
Pill burden and drug toxicities are additional problems contributing
to poor adherence to ART (65) (66). Pill burden is been addressed
by development of fixed dose combination formulations; and
drugs with long half life which can be taken once a day. A strategy
to ensure lifelong compliance to HAART was suggested to be
structured treatment interruptions. The rationale for this approach
was based on the theory that the body immune system can
control low levels of viral replication after suppression by HAART.
Treatment interruption was proved to have no clinical benefit in
the SMART trial (67).
Several approaches are used by health care providers at care
and treatment clinic to monitor patient adherence to ARVs and
prophylaxis of opportunistic infections (OI). The most commonly
used are pill count; pharmacy records; patient adherence to
scheduled visits and clinicians assessment. These methods are
useful monitoring tools when applied in combination.
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Chapter 2: Co-morbidity, Opportunistic Infection and
Interaction
Residents of sub-Saharan Africa experience more ill health than
people in other continents. This is due to the presence of endemic
infectious diseases coupled with HIV-infection and Opportunistic
infections.
Co-morbidity can be defined as occurrence of combination of
disease conditions in the same person at the same time.
Opportunistic infections include all infections and malignancies
which occur when the immune system is weakened. There are
different diseases causative agents found in the tropics, including
viruses, bacteria, fungi, protozoa, helminths and arthropods (68).
A relatively small percentage of these pathogens cause a majority
of serious health effects to HIV-infected persons (69). The
distribution of these pathogens is very diverse depending on
favourable environment, social behaviours and ecological factors
that result in their transmission (70).
HIV and tropical infections affect each other mutually (71). HIV
infection may alter the natural history of tropical infectious
diseases, impede rapid diagnosis, or reduce the efficacy of ant
parasitic treatment (72). Tropical infections may facilitate the
transmission of HIV and accelerate progression from
asymptomatic HIV infection to AIDS. Disease severity depends
on the virulence of the infecting organisms and the competence
of the immune system of the infected person (73). People with
weakened immune system experience much more severe
disease even to causes of mild infections (74). Persons infected
with sexually transmitted diseases especially those associated
with genital ulceration, have increased susceptibility to HIV-
infection due to lack of skin protective barrier.
Activation of the immune system by tropical infections renders
the T-cell lymphocytes susceptible to HIV infection which results
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into HIV disease progression (75). Infections that activate the
immune system and increases secretions of cytokines,
chemokines and chemokines receptors have been shown to
increase the susceptibility and pathogenesis to HIV-virus infection
(76). Diseases like mycobacterium tuberculosis and soil
transmitted helminths which causes up-regulation of CCR5
expression facilitates HIV infection in individuals with these
infections (77). Infections that affect the cellular immune system
have been shown to increase HIV-1 virus replication which results
in disease progression (73).
On the other hand, effects of HIV-infections on tropical diseases
are the result of compromised cellular immune system because
HIV targets CD4+ T lymphocytes and macrophages (37). Thus,
organisms that require intact cellular immune system for their
eradication can easily cause infection (78). The compromised
immune system increases susceptibility to new infection and
reactivation of latent infection (73).  As result, HIV
immunosuppression facilitates infections, increase the rate of
infection, change disease presentation and may complicate
treatment. Most of the major tropical diseases depend on CD4
T-cell lymphocytes and macrophages for their elimination from
the body, thus HIV infection fuels parasitic diseases (79). For
example, risk of parasitaemia and clinical malaria is increased
in semi immune HIV infected adults in malaria regions (80).
Isospora belli and cryptosporidium results into severe chronic
diarrhoea disease in HIV infected persons.
These observations may explain why HIV in sub Saharan Africa
is easily transmitted, and has a faster clinical progression and
high mortality. Again, the above citations can explain the
variations in clinical presentation of HIV in this region. At the
beginning of the epidemic, chronic diarrhoea, wasting (slim
disease), chronic fever without an obvious source, and pulmonary
disease were the syndromes that marked AIDS (68). The clinical
picture of AIDS had changed; the clinical presentation depends
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on the prevalent infectious agents. In holoendemic malaria
regions recurrent malaria fever episodes is most common in HIV
infected persons (80). Enteropathic AIDS is most common in
some areas, usually accompanied with diarrhoea (81).
Tuberculosis, both pulmonary and extra-pulmonary, is the
supreme complicating infection. Herpes zoster is frequently the
first clinical presentation, and has a 95% positive predictive value
for HIV positive status (82). While in other settings septicaemia
due to non-typhoid salmonellae, Escherichia coli and
Streptococcus pneumoniae was the most common diagnosis in
HIV-infected persons (73)
The current understanding of the interaction between HIV and
tropical diseases calls for further research on; patient response
to treatment in presence of co-infection. And, further elucidation
of the manifestation of HIV-related diseases in peripheral (rural)
settings is needed to optimize patient clinical care.
The importance of opportunistic infection to human health was
manifested by the emergence of HIV. The risk of different groups
of opportunistic infections typically increases at different stages
of HIV infection in relation to CD4 T-cell lymphocytes count
depletion. At CD4 T-cell lymphocytes count of 200-400 patients
may develop herpes zoster, tuberculosis and oral Candidiasis.
While at CD4 T-cell lymphocytes count of lower than 200 cells/
µl, several other diseases appear, including Pneumocystis carinii
pneumonia, Mycobacterium Avium complex and others (44). The
highest risk for Opportunistic Infection occurs when the CD4
count is between 50-100 cells/µl. Some of these diseases can
infect people with normal immune systems, but with HIV, they
occur at a much higher rate. It also takes longer for a person
with HIV to recover from a disease than it takes for someone
with a healthy immune system.
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Table 2. 1: Distribution of selected opportunistic infections
reported from studies in sub-Saharan Africa*
COUNTRY
Summary of common Opportunistic Infections
Central Africa Cryptosporidium species, Salmonella species 
Uganda Cryptococcus neoformans, Candida albicans, Cryptosporidium 
species, Salmonella species 
Streptococcus pneumoniae, Mycobacterium tuberculosis, varicella 
zoster virus 
Ethiopia Cryptosporidium species, Salmonella species, Mycobacterium 
tuberculosis 
Kenya Cytomegalovirus, Cryptosporidium species, Salmonella species, 
Streptococcus pneumoniae, Mycobacterium tuberculosis, 
Pneumocystis carinii pneumonia, Mycobacterium Avium complex, 
Toxoplasmosis 
Rwanda Cryptococcus neoformans, Mycobacterium tuberculosis, Malaria 
Pneumocystis carinii pneumonia, varicella zoster virus 
Burundi Cytomegalovirus, Mycobacterium tuberculosis, Pneumocystis carinii 
pneumonia, varicella zoster virus 
Tanzania Cryptosporidium species, Mycobacterium Avium complex, 
Pneumocystis carinii pneumonia, Streptococcus pneumoniae 
Salmonella species, Toxoplasmosis, Mycobacterium tuberculosis 
Malawi Cryptococcus neoformans, Cytomegalovirus, Malaria, Mycobacterium 
Avium complex, Mycobacterium tuberculosis 
Pneumocystis carinii pneumonia, Salmonella species, Streptococcus 
pneumoniae 
Zimbabwe Varicella zoster virus, Pneumocystis carinii pneumonia, Cryptococcus 
neoformans, Cryptosporidium species 
South Africa Pneumocystis carinii pneumonia, Salmonella species, Streptococcus 
pneumoniae, Mycobacterium tuberculosis, Cryptococcus neoformans, 
varicella zoster virus, Candida albicans, Cytomegalovirus, 
Mycobacterium Avium complex, 
Botswana Varicella zoster virus 
Zambia Pneumocystis carinii pneumonia, Mycobacterium Avium complex, 
Mycobacterium tuberculosis, Cryptosporidium species 
Congo Pneumocystis carinii pneumonia, Malaria, Mycobacterium tuberculosis 
Cameroon Streptococcus pneumoniae 
Ghana Cryptococcus neoformans, Candida albicans 
Ivory cost Pneumocystis carinii pneumonia, Salmonella species, Streptococcus 
pneumoniae, Toxoplasmosis, Cytomegalovirus, Mycobacterium Avium 
complex, Mycobacterium tuberculosis, Cryptococcus neoformans, 
Cryptosporidium species 
Gambia Cytomegalovirus 
Senegal Toxoplasmosis 
* Adaptation from Charles B Holmes et al Review of Human Immunodeficiency Virus
Type 1-Related Opportunistic Infections in Sub Saharan Africa: HIV and AIDS 2003
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When the immune system is very weak due to advanced HIV
disease or AIDS, some infections can result into systemic
dissemination (Visceral leishmania) (83). Diseases like AIDS that
spread to involve a number of different organs, posses a great
challenge to clinical management. Similarly, opportunistic
infections appearing at a late stage of HIV infection usually result
in a poor prognosis. For instance, Cryptococcus meningitis can
occur with a CD4 T-cell lymphocyte count < 100 cells/µl and is
associated with high mortality (84).
Mycobacterial tuberculosis is one of the most common
opportunistic diseases that carry the highest cause of morbidity
and mortality in HIV infected patients. HIV and Mycobacterium
tuberculosis have a synergistic interaction; each accentuates
progression of the other resulting in increased morbidity and
mortality in poor settings (86). Atypical mycobacterial also cause
serious disease in immunocompromized patients (86) (87).
Mycobacterium Avium complex is reported to complicate Immune
reconstitution Syndrome in the first 3 months of ART initiation
(88). Its diagnosis requires culture of lymph node fine needle
aspirates. Therefore, it is difficult to diagnose Mycobacterium
Avium complex in areas with limited access to laboratory with
capacity to perform mycobacterium culture.
Various types of fungal infections are also common among HIV-
infected patients. However, Cryptococcus neoformans and
Pneumocystis carinii Pneumonia are the most common life
threatening fungal infection in AIDS patients (89)]. Candidiasis,
despite of being the commonest fungal infection in HIV/AIDS
patients, its overall impact in patient disease progression and
outcome is less documented in sub Saharan Africa. A study in
Uganda found Oral Candidiasis in more than 70% of TASO clients
and was reported to cause mild to moderate discomfort to the
patients (90). However, the study did not describe the clinical
and immunological impact (CD4 increase) of Candidiasis to the
patients after treatment.
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Diagnosis of Opportunistic Infection is variable, some can be
diagnosed clinically and others require laboratory tests for
confirmation. Opportunistic Infection with unique skin lesions like
Candidiasis and Kaposi’s sarcoma can be diagnosed clinically
with certain. While other Opportunistic Infection which present
with multiple signs and symptoms like Tuberculosis,
Pneumocystis Carinii Pneumonia  and Cryptococcus may require
combination of both clinical and laboratory tests to make a
diagnosis. Other diagnosis methods for Opportunistic Infection
include: Microscopic examination, biopsy, X-ray, Blood tests and
other disease specific specialized methods.
Most of the Opportunistic Infections are preventable; either by
use of ART or specific drugs recommended for prophylaxis of
Opportunistic Infection. For example, use of co-trimoxazole can
protect patients from Pneumocystis Carinii Pneumonia,
Toxoplasmosis gondii and some other enteric protozoa.
Fluconazole and Azithromycin protects against Cryptococcus and
M. Avium respectively (91). The main challenge remains to be
adherence to therapy and implementation of the guidelines. In
addition data is lacking on the actual prevalence of Opportunistic
Infection, levels of adherence to therapy and pattern of guidelines
implementation in rural settings.
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Figure 3.1: Water crisis in the study area
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Chapter 3:    Epidemiology and Prevention of HIV and AIDS
inTanzania
3.1 HIV-1 epidemiology in Tanzania
HIV was initially found in a geographic band stretching from
Central Africa across to countries of East and Southern Africa
(14). The epidemic began gradually to move south through
Uganda, Kenya and Tanzania to Southern African countries.  The
first cases of AIDS were described in a hospital in Kagera region
western Tanzania in 1983. Apparently, AIDS was locally
associated with cross border trade between Uganda and western
Tanzania. Initially, HIV affected mostly traders and was named
“Juliana” because of the popular brand of shirts imported from
Uganda at that time. The disease quickly reached all big urban
centres of Tanzania. Prostitutes and their clients suffered from
profuse chronic diarrhoea and profound loss of weight, and then
AIDS was named “Slim disease”. The same “Slim” disease was
already described in Uganda and Zaire (92)
By 1985, the country had an estimated HIV prevalence of 1.3%,
which increased steadily to reach 7% by the end of 2004 (93)
(94). In 2003, between 1.2 and 2.3 million people in the age
group 0-49 years were estimated to be living with HIV/AIDS.
The most vulnerable and affected groups include: women 30–
34 years old; and men 40–44 years old; sex workers; people in
the transport sector, mines, police force, military, prisons and
prisoners; refugees. Occasionally, a few elderly people get HIV-
infection while caring their sick relatives and some forced into
new roles as caregivers without support themselves (95). Urban
residents tend to have higher prevalence as compared to rural
residents. However, overall women are much more affected than
men, and the prevalence increases with age, education level
and wealth quintile (94). Three regions, Mbeya, Iringa and Dar
es Salaam, have a particularly high prevalence above 10% (93)
(33).
28
The major route of HIV transmission in the country is through
heterosexual contact; exposure to infected blood; mother to child
transmission and intravenous drug use. Blood transfusion and
unsafe injections might have contributed substantially to HIV
infection in children and adults in the early years of the epidemic
(96). Needle sterilization by boiling and treatment of severe
anaemia due to malaria disease by blood transfusion was
common practice while methods of HIV screening of donated
blood were not available. Intravenous drug use with needle
sharing and re-use is common in big cities, but is more prominent
in Zanzibar.
3.2 HIV-1 prevention efforts in Tanzania
Tanzania National AIDS Control Programme (NACP) was
established and formally launched in 1988 with the overall aim
of coordinating prevention activities, reducing the incidence of
HIV infection and its associated morbidity and mortality. A further
aim was to establish a link between the government actors and
non-government organizations (NGOs) involved in HIV and AIDS
activities.  This resulted into formulation of HIV and AIDS policies,
Tanzania commission for AIDS (TACAIDS) and adaptation and
implementation of global preventive measures.  NACP receives
technical and financial support from Global Fund to fight AIDS,
Tuberculosis and Malaria, Clinton Health Initiative and PEPFAR
(97). Other organizations like Médecins Sans Frontières are
providing additional funds and technical support.
HIV-1 prevention messages and intervention are provided in
almost all health care service delivery points in different forms.
During routine clinical care patients are informed by health care
workers on the importance of abstinence, being faithful to one
partner, condom use, early HIV diagnosis and treatment of
sexually transmitted infections.
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Pregnant women are counselled and tested for HIV-1 at
Reproductive and Child Health unit, and those who are found to
be HIV-positive receive PMTCT services. While infant feeding
counselling and safer pregnancy messages are provided to all
antenatal attendees routinely as part of the health education
services.
There are also several other prevention programs designed to
cover different at risk population groups in all parts of the country.
Such as the condom use program which aims at improving
access and proper use of condoms, Voluntary  counselling and
testing, work place HIV prevention for health care workers, male
circumcision, and several others. Radio and television broadcast
HIV prevention messages.
Figure 3. 2: Structure of the Tanzania National AIDS Control Program
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3.3    Challenges of expanding Antiretroviral Treatment in
Tanzania
The Tanzania National AIDS Control Program provides guidelines
and coordinates the provision of free antiretroviral therapy for
the whole country. There are major challenges in terms of access
and adherence to ART. Despite the achievements of
regionalization of non-governmental organizations (NGOs) which
have increased ART clinics coverage in the entire country, the
majority of patients in peripheral areas travel long distances to
ART clinics and cannot be retained into care and treatment due
to transport constraints. Although some peripheral ART clinics
use treatment supporters to enhance access and adherence to
ART (61), such strategies are not yet universal in Tanzania.
These challenges are not limited to Tanzania: the use of ART in
sub Saharan Africa (SSA) was delayed for more than a decade
after introduction of combination ART in developed countries.
The delay was a result of concerns that the weak health systems
and adherence problems in SSA populations may lead to
widespread ARVs virological resistance (98) (99). Further
grounds for concern were related to the possibility of
fragmentation of the health system and worsening health care
inequalities on the grounds that there were more cost-effective
interventions available given the limited funding baskets at the
time (100) (101).
There were other numerous health system factors that are still
considered to date as major constraints to introducing ART in
poor resource settings including inadequate service delivery
infrastructure, weak drug regulatory and weak supply systems
and demand side barriers (stigma and affordability) (102). It was
thought that these barriers would result in poor and unsustained
treatment outcomes if not addressed before implementation of
ART services.
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Health worker shortages in the face of HIV/AIDS have been
exposed by the practice of delivering ART through primary health
care services. The shortage of qualified staff to be specifically
trained and become comfortable in managing medical problems
in HIV-infected persons is still a major setback to achieving both
a wide coverage and quality of care. In most rural settings,
patients are managed by less qualified staff, with poor staff morale
caused by logistic difficulties, poor living conditions and lacking
appropriate working tools (103). Such factors were considered
as serious barriers in scaling up ART and thus initially ART were
established in urban hospitals and further delayed in reaching
majority of people in rural areas.
There are still more short comings raised against ART scaling-
up in resource poor settings which are related to unintended
diversion of resources away from other vital health care services
such as maternal and child health care services and nutrition
(104).
The issue of quality of care and sustainability of services is also
considered as a major barrier since sustained funding to ensure
an adequate health care system cannot be met by all SSA
countries. This is evidenced by failure of African Governments
to fulfilling the Abuja declaration to commit 15% of their budgets
to health (105). Large-scale access to HIV/AIDS care and
treatment and prevention programs in SSA countries have been
made possible by donor funded multinational investments. In
addition, since ART programs reduce or delay mortality among
HIV-infected persons, countries will need to contain an ever-
larger numbers of people living with HIV (106). Therefore
financial, health system infrastructure and human resources
capacity need to be strengthened to cope with the ever increasing
demand.
However, these challenges were outweighed by the positive
benefits of which the Global initiatives explicitly set out to achieve
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in order to save lives of HIV/AIDS patients. In SSA millions of
dollars have being directed towards the reduction of medicine
prices, infrastructure improvement, hiring and training of staff.
The World Health Organization catalyzed these efforts by
announcing its aim to help put 3 million people on ART in
developing countries by the end of 2005. In Tanzania, a
rehabilitation program was initiated where laboratories and
consultation rooms were upgraded and provided with all essential
equipment. Capacity building programs were undertaken to train
of health care workers to enable them to perform HIV-testing,
CD4+T lymphocyte counting and HIV/AIDS case management
in all hospitals and selected health centres.
Service delivery challenges related to the complex management
of ART are being addressed through the use of simple fixed
dose ARVs combination regimens, clinical and laboratory
monitoring, access to second line regimens and management
of side-effects.
3.4 Rationale for the PhD research
The pattern and clinical manifestation of HIV and AIDS is
changing continuously due to viral mutations, availability of OIs
drugs and co-infections; and is different from place to place.
The region and population differences in the clinical picture since
the early days of the epidemic were influenced by the endemic
pathogens of the affected population and HIV virus mutations
(107). With the introduction of ART and OIs prophylaxis, the
clinical picture has changed even further. Since HIV/AIDS care
and treatment in resource poor settings entirely depends on WHO
clinical staging, it is justified to always update our knowledge of
HIV/AIDS clinical presentation. The priority is ascertainment of
the heterogeneity of the clinical picture in HIV-infected semi-urban
and peripheral (rural) populations in order to improve on patient
care.
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There is a global focus on the management of AIDS and related
OIs with little emphasis on co-infectious diseases which are
prevalent in resource limited rural areas. This can be explained
by lack of clinical data on actual prevalence rate and impact of
co-infectious diseases on the health of HIV-infected people. To
be effective in providing HIV/AIDS care and treatment in
peripheral (rural) settings the emphasis should be proper
treatment and monitoring of co-infections and or co-morbidity
and treatment of opportunistic infections. Therefore, it is important
to estimate the prevalence of co-infections and HIV clinical
manifestations in HIV and AIDS patients. This subsequently will
result into regular revision of the current HIV and AIDS care and
treatment guidelines.
Patient adherence to ART plays a major role in the effectiveness
of anti-HIV drugs. Poor adherence to treatment results in
ineffective suppression of viral replication which leads to the
emergence of drug resistance viral mutations. Adherence to
therapy can be monitored and managed at a health facility level
by clinicians. Proper monitoring requires understanding of
individual patients’ living context, barriers and influencing factors
to adequate adherence. The current adherence methods in use
were developed without consideration of population
heterogeneity between urban and peripheral (rural) areas. These
differences need to be assessed and find out whether they impact
on adherence.
This PhD thesis addressed the above raised questions through
a comprehensive approach to crucial issues important for the
scaling-up care and treatment services to peripheral (rural) areas.
34
35
Figure 4.1:  A nurse assistant explaining the study to patients
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Part II
Research Goal, Objectives and Principal Methods
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Chapter 4 : Goals and Objectives
4.1  The goal of this study
To conduct research to investigate effects of concurrent parasites
infections and challenges of HIV/AIDS case management on
rural and semi-urban patients in order to contribute information
towards better care for HIV/AIDS patients in Tanzania.
Objective 1
To investigate challenges of HIV/AIDS case management related
to changing HIV-clinical manifestations and parasite co-infection
in rural and semi-urban settings and propose measures to
improve HIV-infected patients care.
Specific objectives
1. To determine the prevalence of parasitic co-infections in HIV-
infected patients in rural and semi-urban settings of Tanzania
2. To study parasitic co-infections in HIV and AIDS patients and
their association with CD4 changes and WHO clinical staging
3. To describe the clinical manifestations of HIV in patients
residing in rural and semi-urban settings of Tanzania
4. To develop validated and simplified HIV/AIDS clinical staging
based on data generated locally in comparison to WHO
clinical staging.
Objective 2
To investigate factors associated with non-adherence to ART in
peripheral (rural) settings in order to provide data for public health
interventions.
Specific objectives
1.  To identify factors associated with non-adherence to ART in
rural and semi-urban settings of Tanzania
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Objective 3
To document experiences and lessons generated in the process
of implementing ART care and treatment at a health centre in
resource limited settings.
1. To study HIV and AIDS case management in a rural health
centre
2. To describe experiences in the process of implementing ART
in a rural health centre
3. To identify and share lessons learned during ART services
delivery at a rural health centre.
4.2  Study area, research approach and principal methods
4.2.1 Study area
The studies were conducted at Tumbi Regional Hospital and
Chalinze Health Centre in Pwani Region, Eastern Tanzania
between April 2008 and June 2009. Tumbi Regional Hospital is
located 40 km from Dar es Salaam, the commercial capital of
Tanzania. The hospital has a bed capacity of 200 beds and serves
as a regional referral Hospital. Chalinze Health Centre is located
70 km from Tumbi Hospital at the junction of the main upcountry
highways with an HIV prevalence of 15%, whereas the
prevalence in Pwani Region was 7%. Both heath facilities provide
services to a mixture of patients from semi-urban and rural
villages. Most residents of Chalinze reside in rural villages and
generate income from farming and trading of different types of
goods.
Tumbi Hospital runs two separate HIV/AIDS clinics for adults
and children. At the time of initiation of this study in April 2008,
Tumbi Hospital had enrolled a total of 3851 and Chalinze Health
Centre had enrolled a total of 450 patients to care and treatment.
Chalinze Health Centre HIV/AIDS care and treatment clinics
started services in May 2007.
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4.2.2 Research approach and methods
The research consisted of three sub-studies carried out
consecutively utilizing different study designs and populations.
Objective 1:
To investigate challenges of HIV and AIDS case management
related to changing HIV-clinical manifestation and parasitic co-
infections in rural and semi-urban settings and propose measures
to improve HIV-infected patient care.
The approach: This was a longitudinal and descriptive study
design and used a structured clinical report form adopted from
the Ifakara clinical surveillance system and IMCI (for children)
was used by the attending clinician (Principal investigator and
the assistant clinician) to document patient disease history, clinical
features, diagnosis, laboratory investigation and treatment.
Objective 2:
To investigate factors associated with non-adherence to ART in
a rural setting in order to provide data for public health
intervention.
The approach
A case-control study was carried out at Tumbi Hospital and
Chalinze Health centre. A structured questionnaire was used to
assess adherence to doses, food instruction and time schedule.
Patients with less than 95% adherence to time schedule; dose
and food were defined as non-adherence cases. Patients with
100% adherence became controls. A structured questionnaire
containing factors known to be associated with non-adherence
to ART in similar settings was administered. Univariate and
multivariate conditional logistic regression were performed to
identify factors associated with non-adherence.
Objective 3:
To document experiences and lessons generated in the process
of implementing ART care and treatment at a health centre in a
resource limited setting.
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The approach: This was a cross sectional study carried out to
study patients registered between May 2007 to 31April 2009.
Two different methods of data collection were used; non-
participant observations of health providers’ performance and
retrospective pre ART and ART registers reviews.
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Abstract
Background
Untreated tropical parasitic co-infections appear to fasten the
progression of HIV-1 disease. However, there have been few
studies to ascertain the interference of parasitic co-infection in
resource limited settings where HIV/AIDS management largely
depend on CD4+T cells counts and WHO clinical staging. This
study, therefore, aimed to determine the prevalence of parasites
and their association with CD4+Tcells changes and clinical
classification of HIV-infection in patients attending care and
treatment in Tanzania.
Methods
Adult HIV-infected patients registering for the first time at HIV/
AIDS clinics were recruited; physical examination and laboratory
tests were performed at baseline and after 6th months. Patients
were assigned a clinical stage and screened for helminths and
Plasmodium sp. co-infection, CD4+Tcells, haemoglobin and HIV-
1 p24 antigen.
Results
Of the 421 HIV-1 infected patients studied, 198 (47.0%) were
co-infected with one or more parasites. While 93/421(22.1%)
patients had helminths only co-infection, and 50/421(12.9%) had
Plasmodium sp only co-infection. Mixed Plasmodium sp and
helminths co-infection was diagnosed in 55/421(13.0%) patients.
Helminths frequently diagnosed included hookworm 65/
421(15.4%), Schistosomiasis 49/421(11.6%), Strongyloides
stercoralis 57/421(13.5%), and Ascaris lumbricoides 54/
421(12.8%). There was no statistical associations between
CD4+Tcells <200/µl, or WHO clinical stage III/IV with parasites
co-infections (AOR 1.2, 95%CI 0.8-1.8). Anaemia was common
in parasite co-infected patients (32.8% vs 18.8%). Parasites co-
infection was associated with risk of anaemia (AOR 2.1, 95%CI
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1.3-3.2). In multivariable logistic regression analysis, baseline
CD4+Tcells <200/µl was significantly (AOR 2.4, 95%CI 1.3-4.7)
associated with CD4+Tcells <200/µl at six months. HIV-1 P24
antigen mean concentration was higher in parasites co-infected
patients (ranges 47.6 to 56.9) compared to patients without
parasites co-infection (5.5).
Conclusions
We have looked at one set of parasites and found high
prevalence of malaria and helminths co-infection in HIV-infected
individuals. Given the available reports on health impacts of
helminths co-infection in HIV/AIDS patients and the anecdotal
reports of helminths health effects even in HIV-uninfected
persons, helminths and other prevalent parasites should not be
ignored in HIV/AIDS programs. And based on local helminths
epidemiology and HIV-infected cohort specific helminths co-
infection prevalence data, mass treatment of soil transmitted
helminths can be confidently incorporated in HIV/AIDS care and
treatment programs.
Introduction
HIV-infection and AIDS in sub-Saharan Africa present with diverse
clinical characteristics reflecting the variety of prevalent endemic
diseases within each area. More than 100 different disease-
causing agents are found in the tropics, including viruses,
bacteria, fungi, protozoa, helminths and arthropods (1). A
relatively small proportion of these pathogens cause the majority
of serious health effects to HIV-infected persons (2). Distribution
of these pathogens is geographically sensitive to favourable
environments characterized by social behaviours and ecological
factors affecting the risk of their transmission (3).
Concurrence of HIV and tropical infections affect each other
mutually. HIV-infection in patients with parasites infection alters
the natural history of parasites diseases pathogenesis, impede
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rapid diagnosis, or reduce the efficacy of anti-parasitic treatment
(4) (5). HIV-1 compromises the cellular immune system through
destroying CD4+Tcells and macrophages (6) thus reducing the
immune system’s ability to resist infection from endemic
pathogens (7). HIV-infected persons are susceptible to new
infection and reactivation of (6) latent infections (1).  As result,
HIV-immunosuppression facilitates infections, increases the
severity of infection, changes disease presentation and
complicates treatment (8). Of particular importance is the
increased risk of parasitaemia and clinical malaria semi immune
HIV-infected adults in endemic malaria regions (9).
In addition to HIV-effects on susceptibility and pathogenesis of
tropical diseases, people living with tropical infections are at
increased risk for HIV-infection and unfavourable disease
progression (10).
Health effects of parasitic co-infections in HIV-infected persons
marked HIV/AIDS clinical manifestations in the early decades of
HIV epidemic. For example, protozoa infections caused chronic
diarrhoea which resulted into wasting (slim disease), chronic fever
without an obvious source, and pulmonary disease syndromes
which marked AIDS in sub Saharan Africa (11) (2).  There is
evidence that helminths species specifically alter HIV disease
progression. Interaction of Schistosome and HIV-infections with
host CD4+Tcells leads to bi-directional effects which are different
from sequelae caused by either infectious agent alone (12).
Helminths infections lead to greater HIV-replication and disease
progression through immune activation of cellular mechanisms
which renders the CD4+Tcells susceptible to HIV-infection
resulting into increased viral load (13). High viral load is
associated with rapid CD4+Tcells death and disease progression
to AIDS (14). Untreated Strongyloides stercoralis causes hyper-
infection syndrome in immunosuppressed patients during the
early stages of immune recovery after initiation of antiretroviral
therapy (ART). It is difficult to distinguish between the clinical
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manifestation of strongyloidiasis hyper-infection syndrome is
distinguished and the immune-reconstitution syndrome induced
by HAART in patients with CD4+Tcells <200/µl; both conditions
are fatal without proper management (15)] (16)]. Ascariasis is
associated with CD4+Tcells <200/µl, an effect which is reversed
by Albendazole treatment (17). Other complications of helminths
and malaria in HIV-infected persons include aggravation of
diarrhoea, anaemia and fever symptoms (18).
Although scientists still debate on the survival benefit of routine
screening and treatment for helminths and other parasitic
infection in HIV-infected patients, helminths and malaria
infections continue to cause morbidity and aggravated mortality
(9). Treatment of parasitic infections could provide an immediate
benefit in areas where both HIV-1 and helminths are prevalent.
Tanzania has overlapping high prevalence rates of HIV and
parasitic infections (19). Scaling up of HIV and AIDS care and
treatment services have become well-established and widely
available, so quality of care becoming increasingly important and
co-infections with latent helminths and malaria an important area
to investigate.
Monitoring of HIV-infected patients in resource limited settings
depends on clinical presentation and CD4+Tcells measurements.
However, there have been few studies to ascertain the
interference of parasites co-infection on CD4+Tcells and clinical
monitoring of HIV-infected patients. This study, therefore, aimed
to determine the prevalence of parasites and their association
with CD4+Tcells changes and clinical classification of HIV-
infection in patients attending care and treatment in Tanzania.
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Methods
Study design
Between April 2008 and March 2009, we studied HIV-infected
adult patients residents of catchments areas of Tumbi Hospital
and Chalinze Health Centre, both located in rural and peri-urban
areas outside of Dar es Salaam, Tanzania.  Newly enrolled HIV-
infected patients attending care and treatment services were
eligible for the study.  Exclusion criteria were age under 18 years,
pregnancy, and patients with obvious severe disease conditions
like Tuberculosis, Cryptococcus Meningitis, Pneumonia and
generalized Kaposi’s sarcoma, or imminent transfer to another
clinic.
A study nurse identified eligible patients after completing routine
clinic registration procedures.  Patients were individually screened
for eligibility after presenting key facts involved in the study;
thereafter a standardized informed consent was administered.
Consenting patients were assigned a study identification number
which was affixed on their clinic card and case file. The patient
was then referred to study clinician for clinical examination.
Study clinicians recorded patients’ clinical history, performed
physical examinations and staging according to the Tanzania
and WHO clinical guidelines for management of HIV and AIDS.
Patients were referred to the laboratory for samples collection.
Blood specimens were collected in EDTA tubes for enumeration
of CD4+Tcells, haemoglobin and malaria smear, part of the
sample was frozen and shipped to Ifakara Health Institute
laboratory for HIV-1 P24 plasma ELISA  assays.
Fresh stool samples were collected in sterilized plastic containers,
and preserved in 10% formalin and were examined within 24
hours by formol-ether concentration techniques (20).  Stool
samples found to contain ova or larvae, intensity of infection
were estimated by quantitative analysis of the egg burden,
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according to the Kato-Katz thick-smear technique. Patients who
could not produce stool on the spot were provided with sterile
plastic containers and asked to bring fresh stool specimen on
their next clinic visit. Sterile plastic containers were also used to
collect clean-catch urine specimen.
Malaria, urine and haemoglobin results were availed to the patient
on the same day; other test results were available on the follow
up visits. Study patients were scheduled follow up visit 14 days
after initial contact to complete ART eligibility counselling and
other assessments.
Patients received standard treatments according to infections
diagnosed: malaria was treated using Coartem ((artemether
20 mg/lumefantrine 120 mg), intestinal helminths were treated
with Albendazole (400mg day one and 200mg 2 subsequent
days), and Schistosomiasis was treated with Praziquantel (40mg/
kg divided into 2 doses 6 hours apart).
After the 14th day contact, study patients were scheduled to
monthly follow up visits regardless of their ART status.  A date
for the 6th month follow up visit was communicated to patients
during their subsequent clinic visits.  Clinical examination and
laboratory procedures performed at initial contact were repeated
at the 6th month visit.
Laboratory procedures
Specimens for CD4+Tcells, haemoglobin, malaria, sputum, urine
and stool samples were analyzed at Tumbi Hospital laboratory.
CD4+Tcells analysis was performed using automated FACS
count (BD Biosciences, California, USA). Biochemistry and
haematological parameters were analyzed using Biochemical
analyzer (Italy) and haematological analyzer (Pentra 80, France)
respectively. Malaria smears were Giemsa stained and
microscopically examined for parasitaemia. Sputum specimens
were stained using Ziehl-Neelsen technique and examined for
mycobacterium tuberculosis.
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Stool samples were fixed using sodium acetate-acetic acid-
formalin (SAF) solution and microscopically examined for
parasites and helminths. Part of freshly passed stool was cultured
in Xylose Lysine Deoxycholate Agar (XLD) media for Salmonella
and Shigella species. Direct microscopic examination was
performed on urine samples. HIV-1 P24 sample analysis was
carried out based on the Ifakara Health Institute adapted
PerkinElmer Life Sciences’s “P24 Ultra sensitive Assay Protocol”
(ELAST® kit) (21)].
Data analysis
Data was entered into Microsoft ®Access, and analyzed using
Stata Intercooled version 9. Standard definitions of severe
immunological suppression were used in terms of the magnitude
of CD4+Tcells decline. Patients with CD4+Tcells below and above
200 cells/µl were categorized as severely and moderately
immunosuppressed. Logistic regression models were used to
generate odds ratios associated with CD4+Tcells <200/µl. An
attempt was made to compare patient groups according to their
species specific helminths infection but small samples sizes
constraints limited the ability to draw statistical inferences.
Ethical approval
The study received scientific and ethical approval from the
Muhimbili University of Health and Allied Sciences Research
Ethics Review Board (Ref.No.MU/RP/AEC/Vol.XII/58) Permission
was granted by Region, District and hospital authorities. Informed
consent for participation was obtained from patients using
Kiswahili language.
Results
A total of 464 subjects were enrolled into the study between
April 2008 and March 2009, 421 patients provided complete
baseline data for analysis. Forty three patients were excluded
from the analysis because of insufficient samples for
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parasitological diagnosis. Patients excluded did not differ from
the remaining patients in terms of socio-demographic
characteristics, CD4 cell counts and clinical presentation at the
time of enrolment.
Baseline characteristics
The mean age of participants was 35.7 (SD 34.6 to 36.9) and
the mean body weight was 51.6(SD 50.0 to 53.1). Women were
the majority of patients 261/421(62%). In total 272/421 (64.6%)
of patients were living in rural areas and a high proportion of all
patients had primary education 336/421 (80%) with no
remarkable differences between patient groups. The majority of
patients used pit latrine for excreta disposal and obtained water
for domestic use from mixed sources (Table 5 1).
Among the 421 HIV-1 infected patients enrolled with complete
data for analysis at initial assessment, 198 (47%) were found to
be co-infected with one or more parasites. Helminths-only co-
infection was diagnosed in 93/421 (22.1%) patients, while 50/
421 (11.9%) patients exhibited Plasmodium sp. parasitaemia but
no helminths co-infection. Mixed Plasmodium sp and helminths
co-infection was diagnosed in 55/421 (13.1%) patients (Table 5
1Table 5 1: Baseline demographic, social and clinical
characteristics of patients by parasites status attended at Tumbi
Hospital and Chalinze Health Centre between April 2008 and
March 2009
Plasmodium sp was the most common parasite isolated 105/
421(24.9%). Of the helminths diagnosed, most frequently
detected were: hookworm 65/421(15.4%), Schistosomas 49/
421(11.6%), Strongyloides stercoralis 57/421(13.5%), and
Ascaris lumbricoides 54/421(12.8%).  Parasites infected patients
harboured one and up to five types of parasites. Multiple parasites
were diagnosed in 89/421(21.1%) patients. Only one patient was
found to harbour all five parasites (Table 5 2).
At the time of enrolment into the study, more than half of the
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patients were in clinical stages III/IV and had CD4+Tcells <200/
µl (237/421(56.3%) and 248/421(58.9%) respectively). The mean
HIV-1 p24 concentration was 15.3 (SD 20.3). A higher HIV-1
p24 concentration was found in patients with lower CD4 cell
counts and WHO clinical stages III/IV. An additional finding was
the high concentration of HIV-P24 antigens in patients with
parasites co-infection (Helminths 47.6pg/ml, Malaria 49.7pg/ml
and mixed helminths /malaria 56.9pg/ml) compared to patients
without parasites (5.5pg/ml). High concentration of HIV-1 P24 is
associated with rapid HIV-1 disease progression.
Effect of parasites co-infection on CD4+Tcells, anaemia and
WHO clinical stages
Overall, parasites infected patients had lower CD4 cell counts
than parasites free patients, but this was not statistically significant
(Table 5 3). Multiple infection was associated with CD4+Tcells
<200/µl (1 vs. 2 parasites: OR 1.9, 95%CI 1.2-3.5; 1 vs. 3-5
parasites: OR 2.3, 95%CI 1.5-10.7) than one parasite co-
infection. The test for trend across ordered groups provided
consistently some evidence that the number of parasites is
associated with low CD4+Tcells counts. However, the result was
only marginally significant (Z = 1.69, p=0.09) (Table 5 2).
The associations of CD4+Tcells <200/µl, anaemia
(haemoglobin<8.0g/dl) and WHO clinical stage III/IV were
examined in patients with and without parasites co-infections
(Table 5 3). No statistical significant differences were observed
between patients with and without parasites co-infection in
association with CD4+Tcells <200/µl. The adjusted odds ratios
for parasites co-infected patients were less than one, except for
patients with mixed malaria and helminths, any helminths,
strongyloides and Ascaris lumbricoides only infections (OR=1.2,
1.6, 1.5 and 2.2 respectively).
The prevalence of anaemia was higher 64/198(32.5%) in parasite
co-infected compare to 42/223(18.8%) in patients without co-
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infection. Parasites co-infection was associated with significant
risk of anaemia (AOR 2.1, 95%CI 1.3 to 3.2). The odds of having
anaemia were high in patients with mixed helminths and malaria
infection, increased by a factor of more than 3 (AOR=3.8, 95%
CI 1.9 to 7.1) compared to patients without co-infection. There
was a strong association between Ascaris lumbricoides and
anaemia (AOR=5.3, 95%CI 1.8 to 15.7). Patients with any of the
helminths infection had almost two times higher odds of having
anaemia (AOR 1.9, 95%CI (1.1-3.3). Similarly, patients co-
infected with hookworm had two times higher odds (AOR=2.1,
95% CI 0.9-6.7) to have severe anaemia; however, this
association was not statistically significant. The associations
between either Strongyloides stercoralis or Schistosomiasis and
anaemia were affected by small samples and did not demonstrate
any statistically significant association with anaemia (AOR 0.4,
95%CI 0.1-2.9, AOR 0.9, 95%CI 0.2-4.5 respectively). However,
it is known that Schistosoma haematobium causes moderate
anaemia. Neither multiple co-infection with any parasites (AOR
1.2, 95%CI 0.8-1.8) nor with single infection (AOR 0.8-1.7, 95%
CI 0.4-5.2) was significantly associated with WHO clinical stages
III/IV.
Changes in CD4+Tcell counts after treatment
Of the 421 patients for whom complete data were available at
baseline analysis, one patient died and 18 patients were infected
or re-infected with parasites during the 6 months follow-up period.
At the end of 6 months follow-up, 196 (98.9%) of those with
parasites and 222 (99.6%) of those without parasites at enrolment
were attended and had complete data for analysis. In total
312(74.1%) patients were started on ART during the period.
We observed an increase in CD4+Tcell counts at six months on
majority of ART patients with and those without parasites (Table
5 4). Patients with parasites at baseline 151/196(77.0%)
experienced increase in CD4+Tcell counts, the majority of whom
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were those with ART treatment 129/151(85.4%). Similarly, for
patients without parasites co-infection, 147/222(66.2%) had
CD4+Tcell counts increased and majority 125/147 (85.0%) were
patients on ART treatment.  The mean CD4+Tcell counts increase
was 111.6(9.0) and 108.6(8.2) in patients with and without
parasite infection at baseline respectively.
The CD4+Tcell counts decreased between enrolment and 6
months follow-up in 45/196(22.9%) and 75/222(33.7%) patients
with and without parasites, respectively. The mean CD4+Tcell
counts decrease was 109.3(SD 14.9) and 101.2(SD 29.9) in
patients with and without parasites, respectively.
Statistical significant difference was observed between patients
with parasites co-infection who experienced CD4+Tcell counts
increase and those whose CD4+Tcell counts decreased
(p=0.001). Similar results were observed in patients without
parasites.
Variables known to be associated with CD4 cell count changes,
were included in multivariable logistic regression analysis,
baseline CD4+Tcells <200/µl was significantly (AOR 2.4, 95%CI
1.3-4.7) associated with CD4+Tcells <200/µl at six months (Table
5 5). New infections with helminths or malaria were not associated
with CD4+Tcells <200/µl at six months (AOR 1.6, 95% CI 0.4-
5.7). This is probably because of low parasite infection intensity
to impact on CD4+ T-cell changes within the follow up period.
The impact of P24 and WHO clinical stages in predicting
CD4+Tcells <200/µl at six months was obviously influenced by
the initiation of ART (AOR 1.0, 95% CI 0.7 to 1.6).
Discussion
This study found malaria and helminths co-infection more
frequent in HIV-infected patients than other parasites. The
prevalence rate of helminths was 22.1% lower than study findings
in other sub-Saharan African settings(22)  (23) but higher than
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results from studies in other rural Tanzania (24) (25). We isolated
frequently hookworm, A. lumbricoides, and Strongyloides
stercoralis in patients with CD4-T cells<200 µ/l and not the
common HIV-related protozoa which marked early AIDS
manifestation as causes of chronic diarrhoea. These findings
could be setting specific or a phenomenon of changing AIDS
manifestation because previous studies have reported higher
prevalence rates of Cryptosporidium and Isospora belli among
HIV-infected patients (22) (26).
The prevalence of malaria co-infection in our study population
was 24.9% higher than findings of previous studies in Eastern
Africa (27) (9). The high malaria parasitaemia in this and other
previous studies points to an important interaction between HIV-
1 and malaria especially in our setting where large population of
severe immunodeficiency patients and endemic malaria coexist.
Malaria is known to cause transitory higher viral load while HIV-
1 causes more clinical malaria, higher parasitaemia and higher
rates of treatment failure in co-infected patients (5)  (28).
Mixed parasites infection is common in areas where various types
of parasites coexist with favourable behavioural and ecological
patterns for transmission. The occurrence of polyparasitism in
the current study showed an inverse relationship with CD4-T
cells<200 µ/l. Health effects of polyparasitism depends on the
types of parasites co-infection, mixed intestinal helminths and
protozoa bring persistent diarrhoea and anaemia. Occurrence
of mixed helminths and malaria infection, malaria can worsen
mild anaemia due to helminths and impact on HIV-infection
outcome.  Although this study did show only a marginal
statistically significant trend towards severe immunodeficiency
as a result of polyparasitism, it highlights an important interaction
especially in settings with higher prevalence of HIV-1 and
parasites infection. Therefore parasites co-infection in HIV and
AIDS patients should not be ignored given the availability of
various reports pointing towards negative health outcomes. Site
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specific assessment need to be carried out to determine the
relevant and abundance of parasites to that particular area to
form the bases for intervention approaches.
It is well established that CD+T-cell<200 µ/l is associated with
high risk of opportunistic infection and poor disease progression
(29). On the other hand parasites co-infection facilitates CD4+T-
cells decline (12) through various mechanisms. This study did
demonstrate a statistical significant association between multiple
parasites co-infections and CD+T-cell <200 µ/l before treatment,
and the odds ratios tended to show some association. Therefore,
parasites co-infection increases the risk of opportunistic infection
in HIV-infected patients. Then, this study finding gives the
indication of a possible strong association in settings with high
infection intensities and their impact on CD4+ T-cell decline.
The association of helminths and CD+T-cell <200 µ/l in this study
was also affected by the low intensities of helminths infection
and re-infection that occurred after treatment. An attempt was
made to analyze each individual helminths species effects but
the samples were insufficiently small to provide basis for
inference. Parasite re-infection and failure to control for the
duration of infection complicated the estimation of the true effects
of helminths on CD4+ T cells decline and clinical manifestations.
It is difficult to determine the duration of infection until the
occurrence of CD4+Tcells decline. Cohort studies in different
settings of high and low parasite prevalence intensities can
provide adequate information on the specific interaction of
helminths and HIV-infection. Health seeking behaviour is one of
the important factors to be considered as cofounders in the role
of helminths co-infection in CD4+Tcell decline. Late presentation
is a common phenomenon in this setting, a majority of patients
goes to seek health care after having advanced
immunodeficiency. Thus, making it difficult to establish which
the cause was and effect between helminths infection and
CD4+Tcell decline.
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Our study population consisted of patients exposed to the
common known risk factors for helminths infection transmission;
largely involved persons with primary level education, limited
access to safe water supply; and used pit latrine, and some did
not use any latrine. Therefore human faeces pollution and high
rates of transmission of soil transmitted helminths is evident in
this population. Improved sanitation combined with de-worming
programs is likely to eliminate helminths transmission. Although
the current de-worming programs are focused on school children
with the highest burden of helminths infection, the prevalence of
helminths in adults is also substantial because of the shift to
adult population (30). Routine mass treatment in HIV-infected
persons can be beneficial and provides an appropriate alternative
public health approach to routine screening and treatment
especially in regions with high burden of helminths.
Anaemia is a common complication which occurs in 20-80% of
HIV-infected patients and is associated with rapid disease
progression and mortality (31). The prevalence of anaemia in
our study was significantly associated with any of the parasites
co-infections. The impact of parasites co-infection on anaemia
was more significant in patients with malaria and helminths
polyparasitism such an association was not demonstrated in
patients without parasites co-infection. HIV-infection can lead to
anaemia in many ways in HIV-infected patients (32). Our results
show the additive effects of parasites co-infection on other causes
of anaemia in HIV-infected patients. In areas where HIV-infection,
helminths and anaemia are prevalent, the interaction of anaemia
and helminths or malaria in HIV-infection need to be emphasized
despite of inadequate diagnosis facilities. In such settings some
patients, even when HIV-replication is controlled by ART, may
continue to experience poor health due to anaemia secondary
to parasites infection.
Increased CD4+Tcells susceptibility to HIV-infection caused by
helminths co-infection was demonstrated by finding of a strong
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association between helminths co-infection and higher HIV-1 P24
antigen concentrations. This positive association can be
explained by the in vivo activation of CD4+Tcells increased
susceptibility to HIV-infection and rapidly HIV-replication in
helminths co-infected HIV-patients compared to helminths
uninfected patients. HIV-1 P24 antigen level >5pg/ml predicts
disease progression comparable to CD4+T-cells<350/µl (33), we
found higher HIV-1 P24 antigen concentration in parasites co-
infected patients and majority of them needed ART for survival.
These findings are contrary to previous reports that showed
higher viral loads in helminths free participants (34).
A noticeable increase in CD4+Tcells was recorded in both
parasites co-infected and uninfected patients between enrolment
and at 6 months. This change cannot be exclusively associated
with treatment of helminths and malaria parasites. Our patients
were given Cotrimoxazole and ARVs together with treatment of
parasites. A statistical significant difference in CD4+Tcells
increase was observed between the parasites co-infected and
uninfected patients. This was because; a higher proportion of
parasites co-infected patients had CD+T-cell <200 µ/l and started
earlier ART compared to uninfected patients. Therefore,
helminths or parasites co-infection treatment benefits are more
expressed if combined with ART and Cotrimoxazole. Cohort
studies comparing very high and very low parasite intensities in
HIV-1 co-infected patients can provide useful information on the
minimum essential burden of parasites responsible for CD4+ T-
cells changes.
Conclusion
We have looked at one set of parasites and found high
prevalence of malaria and helminths co-infection. Given the
available various reports on parasites co-infection in HIV and
AIDS patients, parasites should not be ignored in HIV and AIDS
programs. Incorporation of these programs should not wait the
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conclusion of the ongoing debate on de-worm or not de-worm.
Instead, parasites co-infection in HIV-infected patients’ area
specific prevalence data can be used confidently to guide
program approaches. In low parasite prevalence settings routine
diagnostic screening is recommended and settings with high
parasites prevalence mass treatment should be considered.
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Table 5. 1: Baseline demographic, social and clinical
characteristics of patients by parasites status attended at
Tumbi Hospital and Chalinze Health Centre between April
2008 and March 2009
Characteristics Patients 
without 
parasites 
N=223 
Patients 
with 
Helminths 
only N=93 
Patients 
with 
Malaria 
only N=50 
Mixed 
Helminths 
and 
Malaria 
N=55 
Weight-kg 
mean(SD) 
51.4(1.3) 49.2(1.2) 52.5(1.2) 48.7(1.2) 
Age in years, 
mean(SD) 
35.7(1.3) 36.0(1.3) 35.5(1.3) 34.7(1.3) 
Sex n (%)     
Women  147(65.9) 51(54.8) 30(60.0) 33(60.0) 
Men  76 (34.1) 42(45.2) 20(40.0) 22(40.0) 
Residential status 
n (%) 
    
Rural  146 (65.5) 57(61.3) 28(56.0) 41(74.6) 
Urban 77(34.5) 36(38.7) 22(44.0) 14(25.4) 
Education n (%)     
Incomplete  primary 28(12.6) 8(8.7) 7(14.0) 6(10.9) 
Primary 173(77.6) 78(84.8) 41(82.0) 44(80.0) 
College 22(9.8) 6(6.5) 2(4.0) 5(9.1) 
Marital status n (%)     
Married/cohabiting 104(46.6) 35(38.0) 24(48.0) 21(38.2) 
Single 66(29.6) 35(38.0) 12(24.0) 21(38.2) 
Widowed 47(21.1) 16(17.4) 10(20.0) 6(10.9) 
Separated/Divorced 6(2.7) 6(6.6) 4(8.0) 7(12.7) 
Source of water 
supply n(%) 
    
Home tap                    13(5.8) 4(4.3) 6(12.0) 5(9.1) 
Well or river                43 (19.3) 19(20.7) 9(18.0) 13(23.6) 
Mixed 167 (74.9) 69(75.0) 35(70) 37(67.3) 
Types of latrine n 
(%)          
 
 
 
  
 
 
 
Pit                               170 (76.2) 
 
73(78.5) 42(84.0) 42(76.4) 
Flush                           22 (9.9) 
 
11(11.9) 7(14.0) 10(18.2) 
No latrine 31 (13.9) 8(8.7) 1(2.0) 3(5.4) 
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Table 5. 2: Number of parasites infections, WHO stage and
mean HIV-P24 of HIV/AIDS patients grouped according to
CD4+-T cells categories attended at Tumbi Hospital and
Chalinze Health Centre between April 2008 and March 2009
*Test for trend across ordered groups: Z = 1.69, p = 0.09
Number of parasite species per individual* WHO Stage HIV-1 P24 
Zero One Two Three or 
more 
I/II III/IV Mean (SD) 
   97(43.5) 48(44.0) 17(28.8) 11(36.7) 100(54.4) 73(30.8) 5.4(20.9) 
   126(56.5) 61(56.0) 42(71.2) 19(63.3) 84(45.6) 164(69.2) 30.4(16.2) 
223(100) 109(100) 59(100) 30(100) 184(100) 237(100) 15.3(20.3) 
 
 CD4+T cells count/µl Haemoglobin g/dl WHO clinical stage 
Infection 
status 
CD4<200 (%) AOR*  
(95% CI) 
HB<8.0 (%) AOR* 
(95% CI) 
III/IV (%) AOR* 
(95% CI) 
No infection 126/223(56.5) reference 42/223(18.8) reference 121/223(54.3) reference 
Any 
parasites 
122/198(61.1) 1.2(0.8-1.8) 64/198(32.5) 2.1(1.3-3.2) 116/198(58.6) 1.2(0.8-1.8) 
Malaria only 27/50(54.0) 0.9(0.5-1.7) 12/50(24.0) 1.4(0.7-3.0) 25/50(50.0) 0.8(0.4-1.5) 
Mixed 
helminths 
and Malaria 
33/55(60.0) 1.2(0.6-2.1) 25/55(45.5) 3.8(1.9-7.1) 32/55(58.2) 1.2(0.7-2.2) 
Helminths 
only 
62/93(66.7) 1.6(0.9-2.6) 28/93(30.1) 1.9(1.1-3.3) 59/93(63.4) 1.5(0.9-2.5) 
Hookworm 7/15(46.7) 0.6(0.6-1.8) 5/15(33.3) 2.1(0.9-6.7) 10/15(66.7) 1.6(0.5-4.8) 
Schistosome 6/13(46.2) 0.7(0.2-2.2) 2/13(15.4) 0.9(0.2-4.5) 5/13(38.5) 0.6(0.2-1.8) 
Strongyloide
s stercoralis 
9/14(75.0) 1.5(0.5-4.5) 1/14(7.1) 0.4(0.1-2.9) 9/14(64.3) 1.5(0.5-4.7) 
Ascaris 
lumbricoides 
11/15(73.3) 2.2(0.8-7.2) 8/15(53.3) 5.3(1.8-15.7) 10/15(66.7) 1.7(0.6-5.2) 
 
Table 5. 3: Univariate analysis of the association between
parasites and clinical parameters before initiation of ART
and other treatment of HIV and AIDS patients attended at
Tumbi Hospital and Chalinze Health Centre between April
2008 and March 2009
*Odds ratios adjusted to age and sex
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Table 5. 4: Changes in CD4+Tcell counts between baseline
and after six months of HIV/AIDS patients attended at
Tumbi Hospital and Chalinze Health Centre between April
2008 and March 2009
Table 5. 5: Multivariable Logistic Regression for predictors
of CD4+Tcell <200/µl after six months of follow-up of HIV
and AIDS patients attended at Tumbi Hospital and Chalinze
Health Centre between April 2009 and March 2009
ART 
status 
With parasites at Baseline N=196 No parasites at Baseline N=222 New/re-
infection 
Mean CD4 increase Mean CD4 decrease Mean CD4 increase Mean CD4 decrease 
N (%) Mean(SD) N (%) Mean(SD) N (%) Mean(SD) N (%) Mean(SD) 
ART 129(85.4) 129.9(1.9) 19(42.2) 54.7(2.3) 125(85.0) 118.4(1.9) 23(30.7) 47.5(2.9) 16(88.9) 
Not on 
ART 
22(14.6) 60.2(2.8) 26(57.8) 181.4(2.1) 22(14.9) 66.7(2.5) 52(69.3) 157.8(2.9) 2(11.1) 
Total 151(100) 111.6(2.2) 45(100) 109.3(2.7) 147(100) 108.6(2.1) 75(100) 109.2(3.4) 18(100) 
 
Variables Adjusted OR(95%CI) 
Female 0.9(0.6-1.4) 
Baseline CD4+Tcells counts* 2.4(1.3-4.7) 
Baseline P24 Antigen levels 1.0(0.9-1.1) 
Baseline WHO clinical stage** 1.0(0.7-1.6) 
ART treatment 1.3(0.6-2.6) 
Helminths or Malaria new/re-infection 1.6(0.4-5.7) 
*Reference category CD4+T cells>200/µl.
** Reference category WHO clinical stage I/II.
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Figure 6 1: HIV/AIDS manifestations (Pruritic eczematous eruptions)
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Abstract
Background
Sub Sahara African HIV/AIDS management follows WHO clinical
staging which requires CD4 counts as complement. Lacking CD4
counts facilities in rural health facilities remains a challenge.
Simplified and sensitive clinical staging based on local clinical
patterns is useful to ensure effective care without CD4 counts.
Objectives
To assess whether HIV local-based clinical manifestations can
be used to guide HIV management in settings with limited access
to CD4 counts in Tanzania.
Methods
A cross-sectional study conducted at Tumbi and Chalinze health
facilities, Tanzania, documented clinical manifestations and CD4
counts in 360 HIV/AIDS patients. High frequency manifestations
were used to predict level of immunosuppression with CD4
counts results as ‘Gold standard’. Simplified management groups
comprised of severe and moderate disease stages were formed
based on clinical manifestations and CD4 counts.
Results
Weight loss (48.3%) and chronic cough (40.8%) were the most
reported manifestation in the study population; followed by. Most
symptoms were found to be highly specific (ranging from 56.4%
of weight loss to 98.6% of the combination of cough, diarrhoea
and difficult in breathing) with high positive predictive values
(ranging from 56.8% of fatigue to 90% of the combination of
cough, diarrhoea and difficult in breathing) in predicting severe
immunosuppression. Chronic diarrhoea presented in 10.6% of
patients, and predicted well severe immunosuppression either
alone or in combination with other symptoms (with high likelihood
ratios ranging from 1.83 to 3.27 at 95%CI). Headache, skin and
fungal diseases presented highly but relatively weak in predicting
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immunosuppression. Although, the combination of three
symptoms predicted well WHO stages III/IV with high specificity
and positive predictive values had low sensitivity. The sensitivity
of all the presenting symptoms remained lower than 52%, and
was not improved by including more signs and symptoms in the
analysis.
Conclusions
HIV/AIDS clinics managing large cohorts should review and
validate site specific HIV clinical manifestation in comparison
with CD4 counts and WHO clinical stages. Based on local
experiences simplified guidelines are useful for resource
constrained settings without CD4 counting facilities.
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Introduction
In sub-Saharan Africa, the transmission of Human
Immunodeficiency Virus (HIV-1) occurs mostly through
heterosexual contact and the progression to Acquired
Immunodeficiency Syndrome (AIDS) and premature death is the
reality for people in most poor areas with limited access to
Antiretroviral Therapy (ART) [ 1, 2,3]. HIV disease progresses
from an asymptomatic period of variable duration, through mild
symptoms, to severe disease characteristic of cellular
immunodeficiency [1].
Human Immunodeficiency Virus clinical presentation is known
to be complex since AIDS was described in 1981[2, 3]. HIV can
manifest in a variety of ways depending on the organs affected
and concurrent infections prevalent in the area. The initial clinical
presentation may mimic symptoms of common endemic diseases
in that particular region [4, 5] However, the severity of
manifestation depends on the infected individual’s baseline health
status.  The most significant early manifestation of HIV infection
in Africa was marked by slim disease (diarrhoea and wasting);
tuberculosis; variety of Opportunistic Infections (OI); weight loss,
fever; and dermatological symptoms[2,5,6]. With the exception
of tuberculosis which continues to increase, other AIDS related
diseases are declining gradually due to the widespread use of
OI drugs.
World Health Organization (WHO) has established a four stage
clinical classification system determined by the presence of
Opportunistic Infections and other HIV related conditions [7]. This
classification tried to incorporate most of the AIDS-defining
illnesses occurring in all regions of the world making a global
tool for HIV/AIDS patients care and treatment. It has been a
very useful tool in Sub Saharan Africa at the introduction of
antiretroviral drugs and establishment of HIV/AIDS treatment
cohorts [8]. It helped to capture rapid deteriorating patients and
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initiation of ART in settings with limited diagnostic resources and
less trained clinicians.
Antiretroviral drugs are widely available nowadays and continue
to be scaled up in remote rural areas of sub Saharan Africa [9,
10]. The aim of rapid scale up is to reach more people living with
HIV and AIDS who cannot easily access ART services in urban
hospitals. The main challenges to this plausible strategy include
availability of qualified health workers and laboratory services to
ensure quality care and the monitoring of drug use [11-13]. In
addition, most patients including HIV-infected patients in Sub
Saharan Africa present late for hospital care and treatment when
the disease has advanced [13-15]. By then initial AIDS signs
and symptoms might have been treated empirically through self
medication or use of herbal medicines. Such remedial actions
usually obscure important AIDS clinical features and make it
difficult for the attending clinician to solicit signs and symptoms
to properly stage the patient.
It is evident that HIV/AIDS patients’ management in Sub Saharan
Africa continues to be guided primarily by clinical staging [8, 16,
17] owing to the insufficient availability and/or frequent
breakdowns of CD4 cells count machines, shortage of qualified
medical personnel and laboratory reagents and other logistic
issues and challenges [18]. On the other hand WHO clinical
staging depends on a patient presenting signs and symptoms;
knowledge and skills of the health care worker to make a definitive
staging [8,17,19]. Furthermore, WHO clinical staging is less
sensitive in identifying patients with CD4 cell counts between
200 -350 cells per µL [4, 20]. Therefore, it fails to identify some
patients in need of ART.
Taking into considerations the complexities of HIV clinical
manifestation in our setting which often does not match WHO
clinical staging. Clinicians in lower health facilities, who are
expected to attend to HIV patients in their local settings, need
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simplified and easy to use clinical staging guidelines developed
by utilizing site specific data and clinical experiences. This
approach could effectively support management of HIV/AIDS
patients in ART cohorts based on site specific experiences.
Moreover, the broader availability of ART as well as new
approaches to deal with opportunistic infections call for a review
of the clinical presentations seen within care and treatment
programs in different settings. To date, no studies have proposed
simplified HIV/AIDS clinical staging based on local experience.
With the inspiration of WHO validated HIV/AIDS clinical definition,
our study aimed at developing simplified HIV/AIDS clinical staging
system based on data generated locally from peri-urban and
rural health facilities to allow more effective patient management
and ART cohorts at peripheral level in the absence of CD4 counts.
Methods
Setting and study participants
The study was conducted at Tumbi Regional Hospital and
Chalinze Health Centre in Pwani Region, Eastern Tanzania
between April and December 2008. Tumbi Regional Hospital is
located 40 km from Dar es Salaam, the commercial capital of
Tanzania. The hospital has a bed capacity of 200 beds and serves
as a regional referral Hospital. Chalinze Health Centre is located
70 km from Tumbi Hospital at the junction of the main upcountry
highways with HIV prevalence of 15%. The Pwani Region HIV
prevalence is 7%. Both facilities provide services to a mixture of
patients from urban and rural villages. Most residents of Chalinze
reside in rural villages and generate income from farming and
trading of different types of goods.
Tumbi Hospital runs two separate HIV/AIDS clinics for adults
and children since 2007. At the time of initiation of this study in
April 2008, Tumbi Hospital had enrolled a total of 3851 patients
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to care and treatment. And Chalinze Health Centre had enrolled
a total of 450 patients to care and treatment.
The inclusion criteria for our study population included those
aged 15 and above years; permanent residence to the health
facility catchments area; and first time enrolment to care and
treatment services; no prior use of ARVs and or co-trimoxazole
prophylaxis.
A total of 360 female and male patients consented to participate
in the study. Recruitment of study participants lasted for 3 months.
The current recommended ARV combination regimen for adults
and adolescent include:
AZT + 3TC+NVP or EFV,
D4T+3TC+NVP/EFV
TDF+FTC+NVP/EFV
TDF+3TC+NVP/EFV
Data collection
Each consenting patient was clinically examined in the standard
way that involved a detailed history, physical examination and
laboratory tests. Additional laboratory tests depended on the
suspected diagnosis. Patients’ socio-demographic characteristics
and clinical information were recorded in a structured report form
in addition to routine patient case report forms.
Laboratory procedures
Blood, sputum, urine and stool samples were collected and
analyzed. Blood samples were analyzed for CD4 cell counts,
HIV-1 P24 plasma ELISA assay, haemoglobin, liver and renal
function tests. Blood was collected in EDTA tubes for enumeration
of CD4 cells by using FACS count (BD Biosciences, California,
USA). Biochemistry and haematological parameters were
analyzed using Biochemical analyzer (Italy) and haematological
analyzer (Pentra 80, France) respectively. Thick blood smears
were Giemsa stained and microscopically examined for Malaria
parasitaemia [21]. Sputum specimens were stained using Ziehl-
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Neelsen technique and examined for mycobacterium tuberculosis
[22].
Stool samples were fixed using sodium acetate-acetic acid-
formalin (SAF) solution and microscopically examined for
intestinal parasites. Part of freshly passed stool was inoculated
and cultured in Xylose Lysine Deoxycholate Agar (XLD) media
for Salmonella and Shigella species. A direct microscopic
examination was performed on urine samples. This paper
focuses on CD4 cell counts results in comparison to the WHO
clinical staging.
Data analysis
All data was entered into Microsoft ®Access, and analyzed using
Stata Intercooled version 9.
Each clinical symptom or sign was coded and counted individually
to estimate the frequency of occurrences from every patient.
About 140 different signs and symptoms were recorded. The
frequencies were then used to estimate the proportion of patients
with that particular sign or symptom.
Using CD4 count results and a cutoff point of 350 cells/µL patients
were categorized into two management groups of severe
immunosuppression (CD4+ T-lymphocytes counts below 350
cells per µL) and moderate immunosuppression (CD4+ T-
lymphocytes counts above 350 cells per µL). In addition,
presented signs and symptoms were used to perform WHO
staging. Based on clinical manifestations of the study patients,
we determined the probability of each symptom/sign alone or in
combination of up to three to predict severe immunosuppression
and WHO clinical stages III/IV. The probability were determined
in terms of sensitivity, specificity, predictive values and likelihood
ratio using CD4 cells count level as the “gold standard”. Only
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symptoms which had high frequency and troubled the patient
for more than two weeks were used.
Ethical approval
The study received scientific and ethical approval from the
Muhimbili University of Health and Allied Sciences Research
Ethics Review Board (Ref.No.MU/RP/AEC/Vol.XII/58).
Permission was granted by Region, District and hospital
authorities. Verbal informed consent for participation was
obtained from patients using local Kiswahili language.
Results
Socio-demographic and clinical characteristics
In total, 360 HIV-infected patients consented to participate in the
study and 331(91.9%) patients provided complete data for
analysis. Majority of the patients resided in rural areas
223(67.4%), the others were from semi-urban areas. The median
CD4+ T-lymphocytes counts was 84(IQR 29-127) and 380(IQR
279-536) respectively. There were 191(57.7%) patients with
severe immunosuppression comprising of 68(35.6%) males and
123(64.4%) females.  The median age was comparable in both
groups of patients with severe or moderate immunosuppression.
Patients classified with WHO clinical stage III/IV, 60(42.9%) had
moderate immunosuppression and 54(28.3%) of those with WHO
clinical stage I/II had severe immunosuppression.
Patient’s main presenting symptoms and signs at
recruitment
Frequencies of the most recorded symptoms and signs are
shown in Table 6 2. We report symptoms and signs that persisted
for more than two weeks. Weight loss of more than 5 kg was the
most frequent 160(48.3%), followed by chronic cough
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135(40.8%). Diarrhoea was less common 35(10.6%) in this study
population. Recurrent fever was recorded in 132(39.8%) of the
patients; other symptoms with high frequency included headache
105(31.7%); Peripheral neuropathy 57(17.2%) and fatigue
88(26.6%). patients had various types of skin diseases, but
Pruritic Papular Eruptions was the most common dermatological
condition. Thirty six (11%) patients presented with genital
discharge; 12(33%) of them had sexually transmitted infections.
In addition to major clinical symptoms and signs; 132 (37%)
patients presented with mild non-specific various clinical features.
Major AIDS-defining Opportunistic Infections diagnosed in this
study included: Tuberculosis (15%); Pneumocystis carinii
Pneumonia (7%); Herpes zoster (5%); Cryptococcus Meningitis
(3%); and Kaposi’s sarcoma (3%).
Performance of clinical features to predict severe
immunosuppression
In Table 6 2, Table 6 3 and Table 6 4 the performance of each
AIDS presenting symptom alone or in combination with other
symptoms in predicting severe immunosuppression is
demonstrated. The sensitivities of single main complain were
below 50% except for weight loss of more than 5% and headache
which was 51.8%. However, the specificity of most symptoms
was high with fungal infection and chronic diarrhoea presenting
the highest specificities of 93.6% and 92.9% respectively.
Sensitivity declined with higher combination of major symptoms
per patient (Table 6 3 and Table 6 4). However, the Positive
Predictive values (probability of correct diagnosis) for severe
immunosuppression increased with higher combination.
Patients presenting with chronic diarrhoea had about two times
more likely to have severe immunosuppression (Likelihood ratio
1.83, 95%CI 0.91 to 3.69).  Diarrhoea is an important predictor
of severe immunosuppression even when presenting in
99
combination with other major symptoms (Likelihood ratio ranging
from 1.78 to 4.03, for two and three combination of symptoms).
Most of the symptoms documented as single or in combination
with other symptoms had likelihood ratio of greater than one
indicating their association with severe immunosuppression.
Whereas the likelihood ratio of headache (0.98, 95%CI 0.71-
1.34), fatigue (0.96, 95%CI 0.67-1.38); and the combination of
abdominal pain and fatigue (0.87, 95%CI 0.51-1.49) were less
than one indicating lack of association with severe
immunosuppression.
Since most of the symptoms recorded are not part of the list of
clinical conditions used to determine WHO clinical staging, we
determined the diagnostic properties of combination of three
signs and or symptoms. The results in Table 6 5 show an attempt
to use combination of three symptoms to allocate patients into
WHO clinical stages III/IV. The sensitivities ranged from
4.6%(combination of cough, diarrhoea and difficult in breathing)
to 37.3% (combination of cough, fever, weight loss) however the
predictive values were above 80%, indicating the high probability
of correct allocation of patients to WHO stages III/IV if presented
with multiple combination of major signs and symptoms. The
likelihood ratios were greater than 2 in all the three combinations
indicating that it is useful to use these combinations to clinically
classify patients into WHO stages III/IV.
Discussion
This study attempted to explore the extent to which HIV/AIDS
presenting symptoms at a given location could be used to screen
patients with severe immunosuppression and eventually decide
appropriate model of care for HIV-infected patients in settings
with limited access to CD4 counts. Since the number of HIV/
AIDS patients with unusual clinical presentations continues to
increase due to viral mutations, self medications with
Opportunistic Infection drugs and use of local herbs practices
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which mask the known classical HIV/AIDS manifestations.
Review of clinical manifestations and development of validated
HIV-clinical staging that maximize both sensitivity and specificity
tailored to a particular geographical and endemic area in
comparison to the well established WHO-staging should be
encouraged.
The clinical profiles of about 34% of the study patients were
unique and obscured not fitting with WHO clinical criteria, which
in turn resulted in WHO staging that was inconsistent with their
CD4 cell counts.  The majority of the patients presented with
clinical features of weight loss (and wasting); chronic cough; and
persistent fever for more than 2 weeks. These are common
symptoms and signs which were described as early HIV
manifestation and were significantly associated with sero-
conversion in the first decades of HIV epidemic [23, 24] and
were among the bases of WHO staging together with presence
of opportunistic infection. We also, observed a marked shift in
AIDS clinical manifestation from the classical AIDS clinical
manifestations [23] which previously was marked by profound
weight loss of more than 10% body weight; chronic diarrhoea
and prolonged fever to a mixed picture of signs and symptoms
[23-25]. Although, our patients had reported weight loss, the
weight loss was limited to more than 5 kg and less than 5%
(data not shown) of their initial body weight. The clinical spectrum
seen among the patients in both study sites are quite
representative to the current overall clinical pictures of the HIV/
AIDS patients in the area. The two sites are the only care and
treatment centres in the whole area.
Interestingly, only 10.6% of the patients presented with chronic
diarrhoea which indicates a marked reduction in occurrence of
diarrhoea among HIV/AIDS patients.  Diarrhoea was well known
to affect between 40% and 80% of HIV infected persons and
was also associated with high mortality rates in Sub-Saharan
Africa [24, 26, 27]. The reduction in prevalence of diarrhoea in
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HIV infected people can be explained by the now broader
availability of OIs drugs and co-trimoxazole without prescription.
 Working at care and treatment centres, we recruited newly
diagnosed HIV patients that were all included in the ART cohorts
according to the national control programme. We expected to
record more pre-AIDS signs and symptoms such as generalized
lymphadenopathy, Herpes zoster and mucocutaneous lesions.
Instead, one third of our patients presented with minor non-
specific and often no symptoms. While, at the same time about
one third of the patients had CD4 cell counts less than 350 cells
per µL. Herpes zoster was diagnosed in 5% of patients, most of
them had CD4 cell counts below 200 cells per µL which is contrary
to the common believe that Herpes zoster is a stage II disease.
It is a reality in most rural, poor communities to accept a HIV test
after suffering for a long time and tried on all kinds of remedies
without success. During this time their CD4 cell counts
progressively declined.
Most of the known common HIV related opportunistic infections
were less frequent than expected in this population despite many
patients having CD4 cell counts less than 350 cells per µL. It is
well established that patients at this level of CD4 cell counts
have high risk of AIDS opportunistic infections and AIDS related
cancers [28]. Tuberculosis was diagnosed in only 15% of the
patients despite the high frequency of chronic cough and difficulty
in breathing. Patients with extra pulmonary tuberculosis and
Pneumocystis carinii pneumonia could be missed due to limited
respective diagnostic facilities. The diagnosis of these diseases
was based on sputum and chest x-ray findings. In routine
practice, tuberculosis in HIV-infected patients requires regular
screening at every visit because single screening does not
exclude latent infection that can flare up in the course of HIV
disease progression.
Cryptococcus meningitis and Kaposi’s sarcoma were diagnosed
in only 3% of the patients.  However, the lower rate of HIV related
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cancers can be due to the small sample size of this study. Overall,
the different clinical patterns and frequencies of opportunistic
infections may largely be due to changed approaches in the
clinical management brought forward by (i) the broader availability
of ART in combination with the establishment of care and
treatment centres as part of the national control program and (ii)
the new approaches to handle prophylactically and
therapeutically opportunistic infections also outside the national
HIV/AIDS control program.
Patients with moderate immunosuppression are symptomatically
expected to fit in WHO stages I/II whilst those with severe disease
to be stages III/IV and vise versa. However, according to their
CD4 cell counts, 29% and 49% of patients in clinical stages I
and II were supposed to be in WHO clinical stages III or IV
respectively. Similarly, 37% and 25% of patients in WHO clinical
stages III and IV respectively, were supposed to be in WHO
clinical stages I or II respectively. The level of incorrect
classification found in this study is almost similar to Ugandan
experiences where about 50% of patients were inappropriately
staged [20]. In routine clinical practice WHO clinical stages
determine the direction of case management. Patients in clinical
stages I and II usually receive long time appointments
accompanied by minimum laboratory investigations. While,
patients in clinical stages III and IV usually receive clinical and
laboratory assessment to determine their eligibility to start ART.
Therefore, when a sizable proportion of patients cannot be staged
correctly at first contact in ART clinics, the initiation of ART is
delayed and higher mortality rates can be expected in the first
three months of ART [13].
More than half of our patients were in WHO clinical stages III
and IV which was consistent to the number of patients with CD4
cell counts of less than 350 cells per µL. This is the reality of late
presentation and a challenge to ART programs. Using the cut
off point for severe immunosuppression of CD4 cell counts <350
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cells per µL, comparison is more conservative based on the
Tanzania Care and Treatment Guidelines [16]. Taking into
consideration the high proportion of patients presenting late with
obscured clinical features to care and treatment for the first time,
it appears advantageous to classify patients based on local
understanding of HIV-disease manifestations and to have at least
one CD4 count measurement before initiation of ART. Such an
approach simplifies the process of clinical management and
reduces the chances of missing appropriate staging and hence
avoid delays in starting ART can be avoided.
In our study, skin diseases and fungal infections of the skin and
mucous membranes indicated severe immunosuppression with
a low sensitivity (10.9% and 7.9% respectively). Similarly, these
symptoms were weak predictors of severe immunodeficiency
based on CD4 decline. Although these symptoms are frequently
diagnosed cannot be used to categorize level of
immunosuppression. Most of the symptoms showed low
sensitivity in predicting severe immunosuppression and a high
risk of false negative results, thus many patients with CD4<350
can be missed if these symptoms are used in routine clinical
management. However, these symptoms were highly specific
and high positive predictive values which increased with the
number of symptom combinations for severe
immunosuppression. Therefore the presence of combination of
HIV-specific clinical symptoms in a patient can be used to initiate
ART.
Based on these study findings, exclusive use of WHO clinical
staging of HIV/AIDS patients to decide appropriate model of care,
remains a challenge for clinicians working in settings with limited
access to CD4 counts.  The absence of clinical illness in fitting
with WHO clinical stages cannot be used to rule out the need for
ART. We then recommend use of HIV-specific symptoms based
on local experiences to classify HIV-infected patients into severe
and moderate immunosuppression based on duration of clinical
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manifestations. This classification guided by local clinical
experience - requires further validation. But for patients with
unusual HIV-disease presentation estimation of CD4 counts is
still needed to decide model of care. We recognize the small
sample size used in this study as a limitation. However the
composition of patients from rural and urban settings implies
that the guidelines established can be used at a regional level.
Therefore and besides our current own efforts, more studies
should be conducted to validate the proposed approach of
staging, not only for patients’ classification but also for monitoring
drug side effects and treatment failure in other geographical and
endemic settings.
Conclusion
The broader availability of HIV/AIDS treatment as well as new
approaches to deal with opportunistic infections, we call for a
review of the clinical presentations seen within care and treatment
programs in different settings. Besides applying the WHO clinical
staging care and treatment centres that look after large cohorts
of HIV and AIDS patients information should also develop and
validate site specific guidelines based on local clinical
experiences.
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Table 6.1: Characteristics of patients at first clinical
assessment grouped by CD4 cell count
Table 6.2: Sensitivity, specificity, predictive values and
likelihood ratio of a single symptom to predict CD4d”350
cells/µl
Symptom Patients 
with the 
symptom   
n (%)
CD4=350 cells per µL 
Sensitivity Specificity PPV NPV Likelihood ratio 
(95%CI) 
Weight loss >5kg 160 (48.3) 51.8 56.4 61.8 46.2 1.19 (0.94-1.50) 
Cough  135 (40.8) 44.5 64.3 62.9 45.9 1.37 (1.03-1.82) 
Fever 132 (39.8) 45.0 67.1 65.1 47.2 1.25 (0.95-1.64) 
Headache 105 (31.7) 51.8 56.4 61.8 46.2 0.98 (0.71-1.34) 
Fatigue 88 (26.6) 26.2 72.8 56.8 41.9 0.96 (0.67-1.38) 
Dizziness 70 (21.1) 24.1 82.8 65.7 44.4 1.40 (0.90-2.19) 
Peripheral  
neuropathy 
57 (17.2) 17.3 82.9 57.9 42.3 1.01 (0.62-1.63) 
Diarrhoea 35 (10.6) 13.0 92.9 71.4 43.9 1.83 (0.91-3.69) 
Skin diseases 34 (10.3) 10.9 90.7 61.8 42.8 1.18 (0.61-2.28) 
Fungal infection (skin 
and mucous 
membranes)  
24 (7.3) 7.9 93.6 62.5 42.7 1.22 (0.55-2.71) 
Variable All patients (N=331) CD4>350 cells 
per µL 
(N=140) 
CD4=350 cells 
per µL 
( N=191) 
Median age in years(IQR)  36(12) 36 (30-44) 36 (32-42) 
Male 
Female 117(35.3) 
214(64.7) 
49 (35.0%) 
91 (65.0%) 
68 (35.6%) 
123 (64.4%) 
Residential status 
Semi-urban 
Rural 
108(32.6) 
223(67.4) 
47 (33.6%) 
93 (66.4%) 
61 (31.9%) 
130 (68.1%) 
WHO Clinical stage 
I
II
III
IV  
59(17.8) 
75(22.7) 
95(28.7) 
102(30.8) 
42 (30.0%) 
38 (27.1%) 
35 (25.0%) 
25 (17.9%) 
17 (8.9%) 
37 (19.4%) 
60 (31.4%) 
77 (40.3%) 
Median CD4+ T- cells per µL 
(IQR) 
158(253) 380 (279-536) 84 (29-127) 
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Table 6. 3: Sensitivity, specificity, predictive values and
likelihood ratio of two symptoms to predict CD4d”350
cells/µl
Table 6. 4: Sensitivity, specificity, predictive values and
likelihood ratio of three symptoms to predict CD4d”350
cells/µl
Symptom  Patients 
with the 
symptom   
n (%) 
CD4=350 cells per µL 
 
Sensitivity Specificity PPV NPV Likelihood ratio 
(95%CI) 
Weight loss and 
fever 
96 (29.0%) 31.9 75.0 63.5 44.7 1.27  (0.89-1.82) 
Weight loss and 
cough 
 87 
(26.3%) 
30.9 80.0 67.8 45.9 1.54  (1.04-2.28) 
Cough and fever  74 
(22.4%) 
26.2 82.9 67.6 45.1 1.53  (0.98-2.36) 
Abdominal pain and 
fatigue 
46 (13.9) 15.2 88.1 65.2 41.4 0.87  (0.51-1.49) 
Peripheral 
neuropathy and 
headache 
34 (10.3) 10.9 90.7 61.8 42.8 1.18  (0.61-2.28) 
Fever and diarrhoea 24 (7.2%) 9.4 95.7 75.0 43.6 2.19  (0.89-5.39) 
Weight loss and 
diarrhoea 
24 (7.2%) 8.9 95.0 70.8 43.3 1.78  (0.76-4.18) 
Cough and 
Diarrhoea 
18 (5.4%) 6.8 96.4 72.2 43.1 1.91  (0.69-5.22) 
 
Symptom Patients 
with the 
symptom    
n (%) 
CD4=350 cells per µL 
 
Sensitivity Specificity PPV NPV Likelihood ratio 
(95%CI) 
Cough, fever,  Weight 
loss>5kg 
61(18.4%) 21.9 86.4 68.9 44.8 1.62 (0.98-2.66) 
Weight loss>5kg 
Difficult breathing 
poor appetite 
38(14.5%) 13.6 91.4 68.4 43.7 1.58 (0.83-3.04) 
Headache, Difficult 
breathing,  poor 
appetite 
21(6.34%) 7.9 95.7 71.4 43.2 1.83 (0.726-4.60) 
Fever, headache,  
diarrhoea 
13(3.9%) 5.7 98.6 84.6 43.4 4.03 (0.91-17.90) 
Abdominal pain  
headache diarrhoea 
13(3.9%) 5.2 97.8 76.9 43.1 2.44 (0.68-8.71) 
Fever, diarrhoea, 
 Difficult breathing 
12(3.6%) 
 
4.7 97.8 75.0 42.9 3.27 (0.72-14.92) 
Cough, diarrhoea  
difficult breathing 
10 (3.0%) 4.2 98.6 80.0 42.9 2.93 (0.63-13.59) 
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Table 6. 5: Sensitivity, specificity, predictive values and
likelihood ratio of three symptoms to predict WHO clinical
stages III and IV in HIV infected persons
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Figure 7. 1: A nurse conducting ART adherence counselling to a patient and
treatment supporter
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Abstract
Background
Consideration of adherence to combination antiretroviral therapy
(ART) among patients in resource limited settings is important in
expanding access to ART. Non-adherence is one of the major
causes of treatment failure which leads to increased morbidity
and mortality caused by Opportunistic Infections. Optimal ART
adherence is essential for maximal suppression of viral replication
and long term survival of patients. In order to develop effective
public health interventions in the context of scaling ART services
to rural areas, it is important to evaluate factors associated with
non-adherence among HIV-infected individuals in rural areas.
The purpose of this study was to identify factors related to non-
adherence in rural and semi-urban settings of Tanzania.
Methods
A case-control study was carried out at Tumbi Hospital and
Chalinze Health centre. A structured questionnaire was used to
assess adherence to doses instruction and time schedule.
Patients with less than 95% adherence were defined as cases
while those with more than 95% adherence became controls. A
structured questionnaire containing factors known to be
associated with non-adherence to ART in similar settings was
administered. Univariate and multivariate conditional logistic
regression was performed to identify factors associated with non-
adherence.
Results
A total of 79 cases and 237 controls matched by age and sex
were studied. A high proportion of cases and controls (77.2%
and 84.8%) had good knowledge of ART benefits, adherence
and eligibility. Majority of cases (73.3%) and controls (69.2%)
used public transport to access ART services. More than half of
cases (53.2%) missed clinic appointments due to lack of fare or
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other reasons and was associated with ART non adherence
(mOR 4.2, 95%CI, 2.2-8.1 and 2.1,95%CI 1.2-4.2).  Disclosure
to confidants only and failure to disclose HIV-test positive status
were associated with non adherence (mOR 3.3, 95%CI 1.3-8.5
and 2.3, 95%CI 1.2-7.1).  Alcohol use was associated (mOR
1.9, 95%CI 1.4-3.7) with non adherence to ART. Patients who
were not satisfied with providers were more likely to be non
adherence to ART (mOR 2.0, 95%CI 1.2-3.8).
Conclusions
These findings show that adherence is a dynamic process that
varies depending on region or cohort specific adherence factors.
Adherence improvement strategies need to consider site specific
adherence determinants, patient experiences and concerns.
Background
Tanzania like many other sub-Saharan countries with an
estimated 2 million persons living with HIV and AIDS has the
greatest burden of disease [1], [2].  The prevalence is estimated
at 5.7% in the population segment aged 15-49 years old with
women being highly affected than men [3]. The epidemic shows
regional variations and urban residents have considerably higher
infection levels at 10.9% compared with rural residents 5.2%
[4].
Tanzania benefited from the Global fund for HIV/AIDS, Malaria
and Tuberculosis fund; SDC fund coupled with the U.S.A
Presidential Emergence Fund for AIDS which were made
available in 2004. The National response to HIV and AIDS added
care and treatment in the prevention interventions package [5].
The Government of Tanzania introduced the HIV and AIDS care
and treatment program with the aim of prolonging the lives of
PLHA, to restore their mental and physical functions and to
improve quality of life [1]. Through the National AIDS Control
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Program, the MOH Tanzania adopted a stepwise approach to
scale up antiretroviral therapy (ART) services in the country.  A
pilot HIV/AIDS care and Treatment clinic was started in late 2004
at Muhimbili National Hospital, which was then followed by
establishment of similar clinics in zonal and regional hospitals.
A model integrated care and treatment HIV-clinic was established
at Ifakara Hospital in April 2005 to document experiences and
challenges of providing ART in rural settings through applied
research [6]. This careful rather cautious approach was aimed
at establishing capacity to provide training and supervision roles
to the lower facilities. However, due to increased demand for
Antiretroviral therapy in all parts of the country a quick rapid scale
up strategy was implemented with support from Non-Government
Organizations (NGO). HIV and AIDS care and treatment clinics
were established in selected rural health centres with large
volume of patients.
ART has substantially decreased morbidity and mortality rates
for those with HIV-infection in developed and developing
countries like Tanzania [7]. The use of simpler ARV fixed dose
combination regimens have overcome the prescription
complexities. Thus, lower level health providers can prescribe
ARVs after short term training.
Concerns about poor adherence to combination antiretroviral
drugs (ARV) among patients living in resource limited settings
have been an important consideration in expanding the access
to ART [8]. Mainly due to possibility of poor adherence to
treatment because of inadequate resources and ARV prescription
requirements that the drugs are taken on time, every time and
side effects are managed accordingly [9]. Poor adherence to
ART is one of the major causes of treatment failure which leads
to increases in morbidity and mortality caused by infection with
opportunistic diseases [10], [11]. Good adherence to ART is
essential for maximal suppression of viral replication, avoidance
of resistance and long term survival of patients [12], [13], [2],
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[14]. A minimum of 95% compliance is needed to achieve the
desired virologic outcomes [15], [12].
Many studies have examined adherence to ART in resource
limited settings with varied results due to differences in socio-
cultural and socio-economical contexts of the populations being
studied [16]. Several factors have been found to be associated
with sub optimal adherence to treatment.  Medication factors
such as dosing frequencies and higher daily pill numbers were
highly associated with poor adherence especially before the
development of fixed dose combination [15]. Fixed dose ARVs
combinations (FDC) have reduced the number of pills and the
frequency of intake is reduced to twice daily. In most resource
limited settings commonly use Nevirapine-based HAART with 1
of 2 backbone nucleoside combinations of Stavudine/Lamivudine
or Zidovudine/Lamivudine.  Nevirapine-based HAART delivered
as FDC is convenient to take, easy to adhere to, potent, well
tolerated, and reserves future treatment options in case of drug
failure [17].
Adverse drug side effects, lower level of patient education and
little experience with HIV/AIDS symptoms are strongly associated
with non adherence to treatment in some settings [18], [19].
Understanding of adverse drug side effects can be a challenge
in setting with limited laboratory diagnosis, presence of infection
with similar clinical manifestation and low level of education like
most of the rural areas in sub Saharan Africa.
Good adherence to ART has been shown in sub Saharan Africa
[20], [21], though cannot be generalized to all settings. In some
rural areas where food is scarce and patients have to travel long
distances to seek care, adherence to dietary instructions and
time intervals between doses can result into sub optimal
adherence to ART [22] [23].
Among the psychosocial attributes related to non adherence to
ART include lack of social support, depression, active substance
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abuse and alcohol use, stigma and fear of disclosure of HIV
sero status [24], [25], [26].
A rapid increase in HIV-1 prevalence and testing awareness
among people living in rural and semi-urban communities has
been seen in Tanzania [27].  Rural populations have limited health
care and social service resources. They typically report difficulties
in accessing appropriate health care including HIV care and
treatment services. Rural communities are classified as “closed”
where social ties and networks are very strong. The nature of
these networks decreases the possibility of the likelihood of
disclosure since information is likely to spread fast, then potential
for stigmatization and marginalization following disclosure [28],
[22]. However these social networks are also useful in providing
social and emotional support for People Living With HIV and
AIDS (PLWHA).
Adherence study findings in Tanzania are more likely to be
different between urban and rural or semi-urban settings because
most HIV care and treatment clinics are well established in urban
settings. Rural environments have different demographic,
socioeconomic and cultural characteristics. In order to develop
effective public health interventions in the context of scaling ART
services to rural areas, it is important to evaluate factors
associated with non adherence among HIV-infected individuals
residing in rural areas. The purpose of this study was to identify
factors related to non adherence to ART in rural and semi-urban
settings of Tanzania.
Patients and Methods
The study was conducted at Tumbi regional hospital and Chalinze
health centre in Coast region between May 2008 and November
2008. Majority of the inhabitants of the hospital and health centre
catchments areas are subsistence farmers and traders. They
originated from different ethnic groups and are mainly Islam or
Christians.
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Since adherence to ART in most poor resource settings has been
reported to be more than 95%, ascertainment of factors related
to non-adherence is difficult. Therefore understanding these
circumstances a case-control study design was chosen to be
the best and applied.
We recruited adult patients aged 18-75 years old, who had been
on ART for more than three months and agreed to participate in
the interviews. The process of identification and selection of non
adherence patients (Cases) and adherent (controls) involved use
of pharmacy drug refill records. Patients with one or more missed
drug refills in the past three months were listed and contacted
for interviews. A structured questionnaire consisting questions
on adherence to doses in the past 1-4 days, within the past week;
adherence to time schedule; and the 30 days visual analogy
scale (VAS) was used to determine the level of adherence to
ART. Adherence to doses was calculated as doses taken over
those prescribed. Adherence levels assessed using VAS was
defined as full adherence if the patient marked 9.5 mm (95%) to
10 mm (100%) and non-adherence marked less than 9.5 mm
(<95%) of the prescribed doses taken since last refill. Only
patients who were found non adherence to all by less than 95%
were defined as non-adherence cases. A total of 79 non-
adherence patients were identified, and consented to participate
in the study and matched by age and sex to three adherent
controls.
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Inclusion and exclusion criteria for cases and controls
# Time assumed adequate for patients to be familiar with providers and services
at the clinic
*Time assumed to be adequate for patients to have experienced ART toxicity
and side effects
Data collection
A structured questionnaire was administered to all cases and
controls during a scheduled appointment or routine clinic visits.
The questionnaire was constructed using factors found to be
associated with poor adherence to ART in similar settings in sub-
Saharan Africa [23], [29], [30]. The key risk factors tested
included: stigma, knowledge, provider-patient interaction, and
selected social and behaviour factors. The questionnaire covered
socio-demographic characteristics, social and behaviour factors.
Eight items were developed to assess perceive availability of
social support to cover four themes: emotional support
(confidant), financial support, counselling and care during critical
state. Depression was assessed using a ten items questionnaire
adopted from the version of the Centres for Epidemiologic Studies
Depression Scale (CES-D) accessible at http://
www.chcr.brown.edu/pcoc/cesdscale.pdf.  Two groups of
knowledge was assessed, knowledge of ART (benefits,
 slortnoC sesaC airetirC
 sraey 81= sraey 81= egA
Duration on ART More than 3 months* More than 3 months 
Clinic attendance record Attended same clinic in the last 6 
months# 
Attended same clinic in the
last 6 months 
Level of ART adherence 
(Time schedule and 
dose) 
Less than 95% in all more than 95% in all 
 yrotalubmA yrotalubmA sutats lanoitcnuf tneitaP
Mental state Competent and respond to 
questions  
Competent and respond to
questions  
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adherence, eligibility, names of drugs) and basic prevention
methods (condom use, abstinence, avoid multiple sexual
partners, avoid needle sharing). Stigma was assessed in two
themes: negative self perception and discrimination experiences
at home and in their community.
Statistical Analysis
Data were entered using Microsoft Office Access 2007, cleaned
and transferred to Stata version 10 for analysis. Patient matched
case-control pairs were created using Microsoft Office Excel
2007. Depression was scored as follows: 0 points rarely or none
of the time (< 1 day); 1 point some or a little of the time (1-2
days); 2 points occasionally or a moderate amount of the time
(3-4 days); and 3 points most or all of the time (5-7 days). A case
or control was categorized to have full support if responded to
have support in three or four of the themes, partial support was
one to two, and no support if responded to have no one to provide
any of the four support themes. Knowledge was classified as
good if the respondents answered all the questions correctly.
Distance was defined as the estimated distance of the patient
residency from the study clinic measured in kilometres.
Univariate and multivariate conditional logistic regression was
performed to identify factors associated with non adherence.
The criteria for selection of variables possible for inclusion in
multivariable analysis were based on p value of less than 5%.
The strength of association was measured using matched Odds
Ratios (mOR).
Ethical clearance
The study received scientific and ethical approval from the
Muhimbili University of Health and Allied Sciences Research
Ethics Review Board (Ref.No.MU/RP/AEC/Vol.XII/58).
Permission was granted by Region, District and hospital
authorities. Verbal informed consent for participation was
obtained from patients using local Kiswahili language.
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Results
Demographic characteristics
Three hundred and sixteen patients receiving ART participated
in the study (79 cases and 237 matched controls). The mean
(SD) age was 37.2 (8.5) years. About (64.2%) of the participants
were females, (65.8%) were married or cohabiting and (71.8%)
were Muslims. Majority of the patients completed primary
education (73.4%), unemployed (74.1%) and (59.2%) reported
an average monthly income of less than US$50 (Table 7 1).
Individuals were more often living more than 5km away from the
ART clinic (46.5% d”5km vs. 53.5% e”5km).There was no
significant difference between cases and controls patients with
respect to socio-demographic characteristics.
Univariate analysis
In a univariate analysis none of the socio-demographic
determinants was found to be associated with non adherence to
ART (Table 7 1). Persons with undisclosed HIV-positive status
and those used alcohol were more likely to be non adherence
(Table 7 3). Failure to disclose ones sero status was significantly
associated with non adherence to ART (mOR 2.3, 95%CI 1.2-
7.1). Similarly, individuals who disclosed not to their relatives
were more than three times (mOR 3.3, 95%CI (1.3-8.5) likely to
be non adherence to ART. The odds of patients who drink alcohol
was almost two times greater compared to that of non alcohol
drinkers (mOR 1.9, 95%CI 1.4-3.7). As shown in Table 7 3, taking
care of under-five children, having episodes of depression and
lack of support were not significantly related to non adherence.
The proportion of patients without support was very low in both
cases and controls (12.7% for cases and 11.4% for controls,
respectively). The majority of cases and controls rarely
experienced episodes of depression (65.8% in cases and 72.2%
in controls).
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A high proportion of controls (73.0%) never missed clinic
appointments in the past three months.  While more than half of
cases (53.2%) missed clinic appointments due to lack of fare or
other reasons. Failure to adhere to clinic appointment due to
lack of fare and other reasons was found to be associated with
non adherence to treatment (mOR 4.2, 95% CI 2.2-8.1 and mOR
2.1(1.2-4.2), respectively. Majority of patients (73.3% cases and
64.9% controls) used public minibuses to access ART services.
A very small proportion of cases (8.9%) compared to controls
(44.7%) reside within a walking distance to the ART clinic (Table
7 4).
The proportion of patients with good knowledge of HIV-prevention
was high (68.3%) among controls compared to cases (50.6%).
Patients with poor knowledge of basic HIV prevention were two
times more likely to be non adherence compared to patients
with good knowledge of ART (mOR 2.1, 95%CI 1.3-3.6). A high
proportion of cases and controls (77.2% and 84.8%, respectively)
had good knowledge of ART benefits, ART adherence and ART
eligibility. Self perceived stigma was not associated with non
adherence to ART (mOR 0.9, 95%CI 0.6-1.6) in this study
population (Table 7 4).
Only one variable on patient-provider interaction; satisfied with
providers, was related to suboptimal adherence to ART. Patients
who reported not to be satisfied with health care providers were
two times more likely to be poor adherence to ART (mOR 2.0,
95%CI 1.2-3.8). Spending long time with providers and frequent
meetings with counsellors were not associated with adherence
to ART (Table 7 5).
Multivariable analysis
In the final multivariate conditional logistic regression (Table 7 6)
the following were identified as risk factors for non adherence:
Missed clinic attendance due to lack of fare (adjusted mOR 6.4,
95%CI 2.6-15.9), missed clinic due to other reasons (adjusted
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mOR 1.9, 95%CI 1.1-4.8), disclosure of HIV-positive status to
other than relatives (adjusted mOR 5.2, 95%CI 1.4-19.5) and
failure to disclose (adjusted mOR 2.8, 95%CI 0.6-13.5). Other
factors included poor knowledge of basic HIV prevention methods
(adjusted mOR 1.9, 95%CI 1.1-3.8), Alcohol intake (adjusted
mOR 1.8, 95%CI 0.7-5.2) and unsatisfied with services provided
(adjusted mOR 1.8, 95%CI 1.1-4.2).
Discussion
Previous studies on ART adherence in Tanzania have utilized
cross-sectional and qualitative designs which lack the temporal
order [26], [31], [32]. This case control study design is unique in
this setting where adherence is reported to be more than 95%
[33], [32], making non adherence a rare event. Thus case control
study provides an effective approach to analyze the possible
associations, and potentially determines more accurately which
possible factors are directly related to non adherence, and which
are merely related by a common cause.
In this study, we did not find an association between adherence
to ART and socio-demographic characteristics. Consistent with
previous studies on adherence to ART by gender, age and
education levels [34]. The possible explanation for this finding is
because we studied a homogeneous population with little socio-
demographic and economic variations.
Social support may enhance adherence through encouragement,
reassurance, reinforcement, systematic cues, bolstering of
competence, and motivation or by masking the effect of stress,
anxiety and depression. Social support was not significantly
associated with adherence to ART in this study. This is in contrast
to other previous studies where lack of support was related to
sub optimal adherence to ART [25], [35], [36]. However the
proportion of cases and controls without social support in this
study population was very low which possibly overshadowed the
effect of lack of social support. Equally depression was not
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associated with poor adherence, again, because of low proportion
of cases that experienced depressive symptoms occasionally
(3-4 days) and in most days (5-7 days). In other settings
depression has been an important predictor of poor adherence
[29], [35], [36]. The low proportion of patients without social
support and those who experienced depression symptoms can
be explained by the common phenomenon and sometime is a
requirement for ART patients in rural care and treatment clinics
to have treatment assistants. A treatment assistant reminds the
patient about drug intake times, collecting drugs at health facility
and reporting side effects to the clinicians [6].
Stigma and discrimination against HIV-infected people was
limited to perceived stigma in both cases and controls. Stigma
was reported as self blame and fear to disclose one’s HIV-positive
status to other people which may result into gossips and lose of
friends. Though we found no significant relationship between
such perceived stigma and their treatment adherence, such
stigma may lead to patients’ unwillingness or fear to take medicine
when other people were present. None of the study participants
reported to have experienced stigma and social exclusion
because of HIV-positive status. Other studies has highlighted
stigma to be a barrier to adherence [37], [38]. The high burden
of HIV-infection and more than two decades of AIDS related
deaths in our study population have created awareness and
perception evolution that reduced the magnitude of stigma which
was experienced in first decade of HIV-epidemic. In this study,
majority of patients disclosed their HIV-positive status to few
family members and close relatives. Disclosure was significantly
related to adherence, and this can explain the perceived stigma
in this study population. Fear of disclosure has been documented
to be among the barriers to adherence in African settings [16].
Alcohol consumption is one of the known barriers to ART
adherence in both rural and urban settings [39], [37]. In some
communities alcohol use is believed to temporarily alleviate HIV
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related psychological problems [38]. Alcohol use can result into
forgetfulness of the dose timing and dietary instructions that
accompany some antiretroviral medications. Excessive alcohol
use can cause liver damage and exacerbate antiretroviral drug
side effects. In agreement with these studies alcohol use was a
significant predictor of non adherence to ART in the present study.
Our assessment of alcohol intake was limited to self-report of
consuming alcoholic beverages two or more times in a week,
there were no more questions to quantify the amount consumed.
This can limit the strength of association between alcohol intake
and adherence to ART. However these findings indicate the
importance of regular alcohol counselling and education related
to ART adherence among HIV-patients on ART.
World Health Organization included free access to ART at the
point of service delivery as a component of its public health
approach for reaching universal access in low income countries
[3]. Although coverage rates continue to increase but most rural
residents still have to travel long distances to access ART
services. Transport costs can pose an important barrier to clinic
attendances and ultimately poor adherence to ART [23], [22]. In
this study, most of the patients needed some form of transport
to reach ART clinic. Majority of cases and controls used public
minibuses and therefore had to pay for the transport. We found
that lack of transport money coupled with other reasons
significantly associated with non adherence. Adaptation of the
tuberculosis Direct Observed Therapy as a strategy to improve
adherence to ART in settings like this need to address transport
cost challenges. Dispensing of ARVs in quarterly bases after
the first three months of monitoring adherence and toxicity, can
reduce the transport costs and encourage adherence success.
Where feasible government subsidized transport can reduce
costs to the patients substantially [22]. The ongoing
decentralization of ART services to rural health facilities
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subsequently will reduce the transport needs for majority of the
patients in Tanzania.
Knowledge of basic HIV-infection prevention measures was
significantly associated with adherence to treatment. But
knowledge of ART benefits, adherence requirements and
eligibility was not related to adherence to ART. This contrasting
finding is explained by the high level of HIV-infection prevention
awareness in the communities, and acts as a motivation of ART
adherence. Majority of the patients responded to two questions
that assessed knowledge of ART benefits that ARVs prolong life
and protect against opportunistic infections, compared to
questions on eligibility, adherence schedules, doses and names
of drugs. To remember the complicated names of ARVs, a high
level of education is required; no wonder in some settings
education level is associated with adherence [16]. However, in
practice lack of information and communication about treatment
is the actual barrier to treatment [37]. Although delivery of ART
counselling and education in our study population is done in
local spoken language, but there is a need to explore the content
of Information, Education and Communication (IEC) materials
used and how local disease concepts are communicated.
Understanding and incorporating local peoples’ perception and
feelings towards HIV/AIDS in developing IEC materials is one of
the ways to impact ART knowledge to PLHA and improve
communication between patients and providers.
Good patient-provider relationship and patients’ satisfaction with
health care services have shown positive correlation with
adherence to ART in some settings [40], [41]. Regular contact
with either counsellors or long time spend with providers were
not associated with adherence. But, patients who felt not satisfied
with the time they spend with providers were non adherent to
treatment.  Such patients probably were unable to express their
concerns about medications. In this setting continued patients
counselling tailored to individual needs would improve adherence.
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ART patients taking care of children below 5 years may forget to
take medications due to being busy or stress of caring for the
child. The lack of statistical significant relationship between caring
of under-five children and adherence to ART is because the study
sample is not big enough to segregate this variable between
male and females. Traditionally, daily care of children is the duty
of the females.
Interpretation of our study findings must be taken in the light of
its limitations. The time set of three months adherence was too
short to capture non-adherence risk factors dynamics. Temporary
changes of risk factors making cases or controls become controls
or cases might have affected the analysis but we had to set the
time limit considering the possibility of recall bias.
Conclusions
We found that patient-important barriers to good adherence are
fear of disclosure one’s HIV positive status, use of alcohol, lack
of good knowledge of basic prevention methods, unsatisfied with
providers and transport costs to ART clinic. These findings explain
that adherence is a dynamic process that varies depending on
region or cohort specific adherence factors. Adherence
improvement strategies need to take into consideration site
specific adherence determinants, patient experiences and
concerns. Dispensing of ARVs in quarterly bases can reduce
the transport costs and encourage adherence success for
patients residing far from ART clinics. But more research is
needed on ART adherence and virological suppression in patients
residing far away from ART clinics who may require a three
months ARVs supplies.
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Table 7. 1: Baseline characteristics of the study participants
Characteristic
*Done within the past 3 months
Characteristic
T ota l n (% ) 316(100)
M ed ian age , years(IQ R ) 37(10 .5 )
Fem ale gender, % 64.2
M arried or cohab iting,% 65.8
R e lig ion -Is lam , % 71.8
C D 4 + T -ce ll coun t* 64 .2
C D 4 + T -ce ll coun t, m ed ian(IQ R ) 329(311)
Duration on ART, %
3-12 m onths 34 .5
13-24 m onths 29 .1
25 m onths 36 .4
U nem ployed , % 74.1
Monthly income (US$), %
<50 59 .2
50-150 29 .4
>150 11 .4
D istance to the A R T clin ic , 5km 46.5%
_>
_>
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Table 7. 2: Socio-demographic determinants of Antiretroviral
Therapy adherence among cases and controls
Test for trend across ordered groups Z=-0.07, p=0.95
 Frequency among Univariate 
Characteristics Controls 
n (%) 
Cases 
n (%) 
mOR  
(95% CI) 
All patients 237(75%) 79(25%) - 
Age (years) groups*    
18-29 39(16.5) 14(17.7) 2.19(0.2-22.6) 
30-39 159(67.0) 53(67.1) Reference 
>39 39(16.5) 12(15.2) 0.96(0.4-2.3) 
Sex    
Male 85(35.9) 28(35.4) Reference 
Female 152(64.1) 51(64.6) 1.3(0.2-9.5) 
Marital status    
Married/cohabiting 162(68.3) 46(58.2) Reference 
Single/divorced/widow/separated 75(31.7) 33(41.8) 1.5(0.9-2.6) 
Education level    
No education 41(17.3) 15(18.9) 1.2(0.6-2.3) 
Primary 176(74.3) 56(71.0) Reference 
Secondary/college 20(8.4) 8(10.1) 1.2(0.5-2.9) 
Religion    
Islam 173(73.0) 54(68.4) Reference 
Christian 64(27.0) 25(31.6) 1.2(0.7-2.1) 
Main source of income    
Employed 60(25.3) 22(27.8) Reference 
Unemployed 177(74.7) 57(72.2) 1.1(0.6-2.0) 
Average monthly Income US$    
<50 144(60.8) 43(54.4) Reference 
50-150 66(27.8) 27(34.2) 1.4(0.8-2.5) 
>150 27(11.4) 9(11.4) 1.1(0.5-2.7) 
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Table 7.3: Social and behavioural factors with their
relationship to adherence to Antiretroviral Therapy among
cases and controls
 Frequency among 
 
Univariate 
Variable Controls: n (%) Cases: n (%) mOR (95% CI) 
All patients 237(75%) 79(25%) - 
Taking care of <5 
children 
   
Cares no child 76(32.1) 22(27.8) Reference 
Cares  1-2 children 96(40.5) 44(55.7) 1.5(0.8-2.7) 
Cares  >2 children 65(27.4) 13(16.5) 0.7(0.3-1.5) 
Availability of 
support 
   
Full support 115(48.5) 32(40.5) Reference 
Partial support 92(38.8) 38(48.1) 1.5(0.9-2.5) 
No support 30(12.7) 9(11.4) 1.1(0.8-1.6) 
Depression in the 
past week 
   
Rarely  (<1 day) 171(72.2) 52(65.8) Reference 
Some days (1-2 days) 26(10.9) 14(17.7) 1.8(0.9-3.7) 
Occasionally (3-4 
days) 
23(9.7) 8(10.2) 1.1(0.5-2.6) 
Most days (5-7 days) 17(7.2) 5(6.3) 1.0 (0.4-2.9) 
Disclosure Status    
Disclosed to many 
people 
61( 25.7) 17(21.5) Reference 
Disclosed to 1-2 
relatives 
146(61.6) 42(53.2) 1.0(0.5-1.9) 
Disclosed not to 
relatives 
19(8.1) 14(17.7) 3.3(1.3-8.5) 
Not disclosed to 
anyone 
11(4.6) 6(7.6) 2.3(1.2-7.1) 
Drinks alcohol     
No 206(76.9) 31(64.6) Reference 
Yes 62(23.1) 17(35.4) 1.9(1.4-3.7) 
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Table 7. 4: Treatment and care seeking influencing factors
and their association with adherence to Antiretroviral
Therapy among cases and controls
Variable Frequency among
Controls: n (%)
Frequency among
Cases: n (%)
Univariate mOR
(95% CI)
Self perceived stigma
N o 129(54.4) 35(44.3) R eference
Y es 108(45.6) 44(55.7) 0 .9 (0 .6-1 .6 )
ART knowledge
G ood 201(84.8) 61(77.2) R eference
P oor 36(15.2) 18(22.8) 1 .6(0 .9 -3 .0)
Knowledge of basic prevention
methods
G ood 162(68.3) 40(50.6) R eference
P oor 75(31.7) 39(49.4) 2 .1(1 .3 -3 .6)
Distance from ART clinic (Km)
Less than 6 km 106(44.7) 41(51.9) R eference
6 km and m ore 131(55.3) 38(48.1) 0 .7(0 .4 -1 .2)
Type of transport used to clinic
W alk 24(10.1) 7(8 .9) R eference
B icyc le 16(6 .8) 7(8 .9) 1 .5(0 .4 -5 .4)
M otorcyc le 33(13.9) 7(8 .9) 0 .7(0 .2 -2 .4)
B us 164(69.2) 58(73.3) 1 .2 (0 .5-2 .9 )
Duration from HIV +test to
seeking care
W ith in m onth of tes t 154(64 .9) 47(59.5) R eference
1-12 m onth afte r tes t 67(28.3) 23(29.1) 1 .1(0 .6 -1 .9)
>12 m onths afte r tes t 16(6 .8) 9(11 .4) 1 .8 (0 .8-4 .2 )
Adherence to clinic
attendances
N ever m issed 173(73.0) 37(46.8) R eference
M issed due to lack of fa re 33(13.9) 28(35.5) 4 .2(2 .2 -8 .1)
M issed due to other reasons 31(13.1) 14(17.7) 2 .1 (1 .2-4 .2 )
Duration on ART (in months)
3-12 76(32.1) 33(41.8) R eference
13-24 71(29.9) 21(26.6) 0 .7(0 .4 -1 .3)
25 90(38.0) 25(31.7) 0 .6 (0 .3-1 .2 )_>
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Table 7. 5: Patient-provider interaction factors and their
relationship with Antiretroviral Therapy adherence status
Variable Frequency among 
Controls 
Frequency among 
Cases 
Univariate 
mOR (95%CI) 
Meeting with 
counsellors in past 6 
months 
   
Not at all 179(75.5) 58(73.4) Reference 
1-5 times 49(20.7) 18(22.8) 1.2(0.6-2.2) 
More than 5 times 9(3.8) 3(3.8) 1.2(0.3-4.7) 
Time spend with 
provider 
   
Less than10 minutes 68(28.8) 18(22.8) Reference 
More than 10 minutes 168(71.2) 61(77.2) 0.7(0.4-1.3) 
Satisfied with providers    
Yes 195(83.0) 57(72.1) Reference 
No 40(17.0) 22(27.9) 2.0(1.2-3.8) 
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Table 7. 6: Final multivariable conditional logistic regression
model for the factors associated with non-adherence to
Antiretroviral Therapy
*Adjusted to all variables in Table 7 2, Table 7 3, Table 7 4, Table 7 5
Factors Adjusted mOR(95% CI)* P-value 
Adherence to clinic  
attendances 
  
Never missed Reference  
Missed due to lack of fare 6.4 (2.6-15.9) <0.001 
Missed due to other reasons 1.9 (1.1-4.8) 0.05 
 
Disclosure Status 
  
Disclosed to many people Reference  
Disclosed to 1-2 relatives 1.2 (0.5-2.7) 0.642 
Disclosed not to relatives 5.2 (1.4-19.5) 0.015 
Not disclosed to anyone 2.8 (0.6-13.5) 0.201 
 
Drinks alcohol  
  
No Reference  
Yes 1.8 (0.7-5.2) 0.043 
Knowledge of basic prevention 
methods 
  
Good Reference  
Poor 1.9(1.1-3.8) 0.050 
Satisfied with providers 
services provided, time spend 
and issues discussed 
  
Yes Reference  
No 1.8(1.1-4.2) 0.034 
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Figure 8. 1: The study scientist examining a patient at Tumbi Hospital
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Abstract
Background
Implementation of ART services at Health centres in Tanzania
were delayed due to several reasons including shortage of
qualified staff, inadequate infrastructure and logistics problems.
However, patients from peripheral (rural) areas experienced
difficulties in accessing ART services due to long distances from
clinics. NACP and NGOs embarked on ART services scale-up
program aimed at improved ART availability and accessibility.
Through this program ART services were established at Health
Centres and selected dispensaries. However, no previous
documented experiences existed at country level to guide
provision of services. Therefore, this study was designed to
gather experiences and share lessons learnt with other health
care providers and program implementing partners.
Methods
This was a descriptive cross-sectional study involved patients
enrolled to ART services between May 2007 and April 2009.
Data collection involved observation of health providers’
performance and retrospective ART and Care patients’ registers
review.
Results
During the study period, 611 care and 284 ART patients were
attended. Majority of patients 762/895 (85.1%) were adults aged
25-45 years, while children were 27/611 (4.4%) pre ART and 16/
284 (5.6%) ART. In total 550/895 (61.5%) patients had CD4+T
lymphocytes d”350/µl the cut-off point for initiating ART. The
frequency of symptoms was noted to significantly decrease with
increasing CD4 counts (p<0.001). However, numbness, parotid
enlargement and genital discharge were not related to patient
level of CD4+T-lymphocytes counts. Papular Pruritic eruptions
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98/282(34.8%), Tuberculosis 86/282(30.5%) and Oesophageal
Candidiasis 37/282(13.1) were the most diagnosed AIDS defining
illnesses. Sixteen patients on care died and 30 were lost to follow
up. Overall the clinical management was poorly performed.
Conclusions
In conclusion ART services can successively be provided at
health centre level and encourages HIV-infected persons to seek
care. However, clinicians need regular clinical mentorship and
supportive supervision.
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Introduction
Tanzania HIV/AIDS care and treatment services were initially
focused at District and other high level health facilities (MOH
2005). Health centres were left out due to several reasons
including lack of qualified clinical staff, lack of adequate
infrastructure and supply logistics problems (Wyss 2004), (
Katabira &  Oelrichs 2007), (Kober & Van Damme 2004).
However, many patients from remote rural areas experienced
difficulties in accessing care and treatment in District hospitals.
The majority of patients in rural areas travel long distances to
reach District hospitals and endure long waiting times in queues
at the clinics (Hardon et al. 2007).  As a result, patients fail to
follow routine appointments and failed to adhere to appointment
schedules for ART treatment. Tanzania National AIDS Control
Program (NACP) challenged with the rapid increase of AIDS
patients in District and referral hospitals recognized the need to
establish ART services at Health Centres and other selected
lower health facilities aimed at improving access and adherence
to ART, reduction of loss to follow up and stigma (MOH 2005).
Consequently, NACP and Non-Governmental Organizations
(NGO) implemented a regionalization approach aimed at
increasing the speed of ART scaling-up process to cover the
entire country. Each NGO was assigned specific regions to
implement ART services and related programs. A national ART
accreditation protocol was developed and used to assess health
care facility infrastructure capacity, available human resources
and potential volume of HIV/AIDS patients. Through this process
Chalinze health centre was accredited to provide ART services
which were commenced in May 2007.
A typical Health Centre has 15 bed capacities and is managed
by an Assistant Medical officer supported by medical assistants
and assistant nurses. Laboratory services at the health centre
are limited to basic haemoglobin, sputum, urine and stool
151
microscopic examinations. Usually a Health Centre serves as a
third level of health services referral hierarchy, followed by
dispensary and village health post. A Health Centre is expected
to cater for a population of 50,000 people which is approximately
the population of one administrative division in Tanzania.
However concerns have been raised about the quality of ART
services delivered in Health centres due to inadequate  human
resource capacity and lack of laboratory facilities  for  monitoring
CD4 + T-lymphocytes testing (Van Damme et al. 2006), (Kober &
Van Damme 2004), ( Katabira &  Oelrichs 2007). Furthermore,
establishment of care and treatment clinics at lower levels of
health care facilities poses challenges on the health system ability
to pull enough resources (Morrison 2002) to cope with increased
logistics demands, supply chain management and supportive
supervision. Such challenges can be addressed by health centre
patient treatment cohort analysis. Currently there is no published
data on health centre experiences of delivering ART services in
Tanzania. This study therefore, was designed to gather
experiences and share lessons learnt with other health care
providers and program implementing partners.
The major objectives of this study were: (1) to describe HIV and
AIDS case management at a rural health centre level in Tanzania,
(2) to assess short-term outcomes of patients attending care
and treatment at a health centre, (3) to describe experiences
and lessons learned in the process of implementing ART in a
rural health centre in Tanzania.
Methods
2.1. Setting
Chalinze Health Centre is the largest rural Health Centre in
Bagamoyo District in Pwani Region, Eastern Tanzania. The health
centre is located at Chalinze town, 80 km and 70 km from
Bagamoyo District and Tumbi Region Hospitals, respectively.
152
The Health centre serves inhabitants of seven villages around
Chalinze town with approximately population of 300,000 people.
Most residents are farmers and small scale traders and rely on
health services delivered by the Health centre. The HIV-1
seroprevalence in 2007 was 15%. The health centre started
offering ART services in May 2007 with financial support from
President’s Emergency Plan for AIDS Relief (PEPFAR) and
technical support from Columbia University Mailman School of
Public Health (ICAP). ICAP provided clinical training and
mentorship, renovation of the health centre building to create
rooms for ART services, procuring equipment and supplies, and
establishing systems to support laboratory services and data
collection. The staffs at health centre involved with ART services
delivery were trained for two weeks using training modules
accredited by Tanzania National AIDS Control program.  ART
treatment started under the supervision and mentorship of
experienced Doctors and Nursing officers from Tumbi Regional
Hospital in collaboration with ICAP staff. The ART start-up clinical
team comprised of one clinical officer (with diploma in clinical
medicine), two medical attendants (nurses), one pharmaceutical
assistant and a data cum registry clerk.  By the end of April 2009,
858 adults and children were enrolled for ART services.
2.2 Clinical services process
ART services are provided daily Monday to Friday, two days in a
week are dedicated to newly enrolled patients to receive
counselling, clinical examination and laboratory evaluation.
Laboratory services at the health centre are limited to basic
haemoglobin, blood, urine, sputum and stool microscopic
examinations. CD4+ T lymphocytes, haematology and
biochemistry analysis were sent to Tumbi regional hospital two
times every week and results were obtained in the following week.
Reasonable referral networks existed with dispensaries, village
health posts, Bagamoyo District and Tumbi Regional Hospital.
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Patients starting to use ARVs are given an appointment according
to treatment guideline to be seen at the clinic after two weeks.
From then on, provided there are no side effects, patients are
seen and given ARVs at 4 weeks intervals. Clinical officers are
mainly responsible for patients’ clinical examination, treatment
initiation, regimen changes and follow-up patient clinical
evaluation. Assistant nurses provide counselling according to
standardized protocols.
Patients were eligible for ARVs if were symptomatic (WHO clinical
stage III or IV), and have CD4+ T lymphocytes count of <200µl.
Patients are required to meet a number of additional criteria
including: completing ART counselling sessions, nominating a
‘treatment assistant’ to assist with adherence. The first-line ART
regimen in Tanzania is a fixed-dose combination of stavudine
(d4T), lamivudine (3TC) and nevirapine (NVP) (Triomune). In
case of d4T- and NVP-related side effects, the respective
alternatives are zidovudine (AZT) and efavirenz (EFV). ART is
offered free of charge in all public facilities in Tanzania, including
Chalinze health centre.
ART monitoring is done using standardized National monitoring
tools which include care and ART registers. Patients are issued
identification cards, upon registration, bearing demographic
characteristics and dispensed ARVs regimen or Cotrimoxazole
and appointment date for the subsequent clinic visits.
Standardized treatment outcomes are monitored every month
in the patient master cards and updated each month in the ART
register; thereafter quarterly reports are sent to the Ministry of
Health.
2.3. Data collection
Two different methods of data collection were used; non-
participant observations of health providers’ performance and
retrospective pre ART and ART registers reviews. Health
providers’ performance indicators are summarized in the following
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Table 8 1. The researcher took the role of non-participant observer
in the consultation room. Verbal Informed Consent was obtained
from patients and the attending clinicians. Observation check
list was used to systematically document the clinician’s actions
and approaches. The check list was developed based on the
National HIV and AIDS treatment guidelines (MOH 2005) and
contained minimum set of actions which must be carried out for
the   care given to be classified as adequate quality care.
Table 8. 1: Clinical actions assessed by observations
A sample of 40 patients categorized in two groups of newly
enrolled (first clinic attendees) and continuing clients were
conveniently selected for this assessment. This is to allow
collection of comparable and triangulation of data.
The concern, however, is that people who know that they are
being observed may change their behaviour. This challenge was
addressed by making observation to last long enough (2 months),
thereby making clinicians to eventually revert to their normal
behaviour. It has been established that few people have the
capacity to keep up a “perfect“ artificial behaviour for extended
periods.
Data collected from pre ART and ART registers reviews included
demographic characteristics, signs and symptoms at first
enrolment to the clinic, laboratory results, treatment regimen start
and stop dates and the reason for change, and reasons for
treatment termination. Patients case report forms (CT2) which
Score History 
taking 
Physical 
examination 
Ordering 
laboratory 
tests 
Prescribing 
therapy 
Patient 
education 
Excellent 4 4 4 4 4 
Good 3 3 3 3 3 
Satisfactory 2 2 2 2 2 
Inadequate 1 1 1 1 1 
Never done 0 0 0 0 0 
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records patients demographic and clinical parameters, facility
and patient registration codes and clinic visit dates were reviewed.
2.3. Data analysis
Data was entered into Microsoft ®Access, and analyzed using
Stata Intercooled version 9. The observation scores were
compiled for each clinical process and the proportion of cases
in which it was executed. A minimum set of actions were set
according to the category of the patients (New or follow up case)
all of which must be carried out for a case to have been handled
with adequate quality of care. The cumulative personal years of
follow-up was calculated from the date of enrolment to cut-off
point of follow-up or lost to follow-up or death of the pre ART
patients. Lost to follow-up was defined as three or more
consecutive months since last scheduled appointment. Patients
taking antiretroviral drugs (ARVs) were excluded from mortality
rate analysis because no death occurred and ARVs would
confound findings.
Ethical clearance
The study received scientific and ethical approval from the
Muhimbili University of Health and Allied Sciences Research
Ethics Review Board (Ref.No.MU/RP/AEC/Vol.XII/58) Permission
was granted by Region, District and health centre authorities.
Informed consent for participation was obtained from patients
using Kiswahili language.
Results
Over a period of about 25 months, a total of 895 pre ART and
ART patients were attended at Chalinze health centre. Of the
ART patients 284 were still active during the study period and
provided complete data for analysis. Thirty (4.9%) patients on
care and 55 (19.4%) on ART were lost to follow-up. The quarterly
cumulative numbers of patients enrolled and retained into care
and ART are displayed in details in Figure 8 1.
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Patients’ characteristics are detailed in Table 8 2. Majority of
patients were adults’ aged between 25 to 45 years. Only 27/611
(4.4%) pre ART and 16/284 (5.6%) ART children were enrolled
during the study period. Majority of the patients were females
622/895 (69.5%), males had higher mean weight compared to
females (mean 53.3 and 46.3 respectively).Most patients
reported to be working 605/895(67.6%) and 281/895(31.4%)
were ambulatory. At presentation to the clinic, majority of patients
550/895 (61.5%) had CD4+T-lymphocytesd”350 and 531/
895(59.3%) in WHO clinical stages III/IV. Sixteen patients on
care died at different times during the study period, contributing
to mortality rate of 2.13(95%CI 1.31 to 3.48) per 100 patient-
years, and 23/284 (8.1%) ART patients died, resulting onto
mortality rate of 0.042(95%CI 0.01-1.01). More than half (152/
238(63.9%)) of patients on ART had CD4+T cells<200/µl.
A wide range of signs and symptoms occurred and were recorded
at enrolment. Patients whose CD4+T-lymphocytes counts were
low had more symptoms and signs than those with relatively
higher counts. The frequency of symptoms was noted to
significantly decrease with increasing CD4 counts. However,
numbness, parotid enlargement and genital discharge were not
related to patient level of CD4+T-lymphocytes counts. Many
patients reported weight loss, skin itching or rashes which was
followed by fever, body weakness and productive cough. Chronic
diarrhoea was found in only 47/895(5.2%) patients was
significantly related to CD4+T-lymphocytes counts levels
(p=0.02). (Table 8 3).
Majority of patients enrolled for care received HIV test from
Voluntary Counselling and testing centres (VCT) (39.4%),
followed by outpatient (24.2%) and MCH/PMTCT (12.6%) (Figure
8 2). Patients at the outpatient, inpatient and Tuberculosis units
were tested through provider initiated testing and counselling
program. Surprising no patients were HIV-tested at sexually
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transmitted infection clinic (STI clinic) despite of training all clinical
staff at the centre in provision HIV testing.
Overall 282 cases of AIDS defining illnesses (ADIs) were
diagnosed and treated during the study period. The most frequent
ADIs cases were Papular Pruritic eruptions 98/282(34.8%),
Tuberculosis 86/282(30.5%) and Oesophageal Candidiasis 37/
282(13.1). Less common ADIs were Herpes zoster 16/282(5.7%),
HIV encephalopathy 16/282(5.7%), HIV wasting syndrome 15/
282(5.3%), Kaposi’s sarcoma 11/282(3.9%) and Pneumocystis
Pneumonia 3/282(1.1%) (Figure 8 4).
Clinicians were trained to use three methods to evaluate patients’
eligibility to start ART: WHO clinical staging, CD4+T-cells count
or combination of these two. About 45.7% of patients were
evaluated using CD4+T-cells counts while WHO clinical staging
only was used in 39.1% of patients, and both methods were
applied in 15.2% of patients (Figure 8 3).
The average consultation time was 4 minutes. Seventy-five
percents of the consultations lasted less than 5 minutes and
none more than 10 minutes. All consultations were characterized
by inadequate history taking and lacked explanations of the
disease, prescription and or the ordered laboratory investigations.
Physical examination in terms of inspection and palpation head
to toe was performed in 39% of the patients in a sitting position
and 6% were asked to lie on examination bed. Unless the patient
volunteered to show a lesion on the body, most often clinicians
never solicited for abnormalities. Most prescriptions were
repetitions of the previous medications and not the diagnosis of
the day. Occasionally patients would remind the clinician to
prescribe additional medicines for the new complaint.
Discussion
Our study presents quantitative and qualitative findings; the
qualitative findings were enlisted through observation of health
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care providers but did not collect data on patients’ perceptions
of the services provided. We found that clinical management
was poorly performed, marked with inadequate physical
examination, inaccurate history taking and short consultation
times. Despite expectations that clinical practice could be
improved after ART training, we did not find any evidence to
support such hypothesis.  This study is not the first article to
report on poor technical quality of care: similar practices have
been reported by studies conducted in primary health care
facilities in Tanzania in relation to malaria case management
(Gilson et al, 1993) (Nsimba et al. 2002). Clinical mentorship
and regular supportive supervision programs need to be
strengthened in order to shape the clinical practice in peripheral
health care facilities.
At Chalinze health centre we found an excellent referral system
networks used to access ART services by patients from nearby
dispensaries and the transportation of samples to Tumbi hospital
laboratory. Similar referral mechanisms can be established in
any sites linking HIV-infected patients with care and treatment
centres.
The large number of patients enrolled for HIV/AIDS care and
treatment at Chalinze health centre within the short period of 25
months is alarming. However, it may be the result of increased
awareness of ART health benefits, decreased HIV stigma due
to ART availability close to patients’ homes and the big burden
of AIDS in rural population (Posse et al. 2008). HIV/AIDS
associated mortality rates in rural areas of Tanzania is known to
be more than 15 times compared to HIV-negative deaths rates
(M. Urassa et al. 2001). ART services availability within short
distances encourages patients who were to travel for long
distances or even days to seek ART care and treatment. The
proximity to services motivates entry to care and encourages
retention in care.
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Our findings point to already established facts that, it is possible
to provide ART services in rural resource limited settings using
existing health care workers after up-grading their skills (Wyss
2004). Despite of the weakness and short comings documented
by this study, clinic attendance was growing steadily, an indication
of high demand for services and some degree of patients’
satisfaction was noted with the services rendered. Patients
studied experienced numerous signs and symptoms whereby;
cough, fever and non-specific skin rashes were the most
frequently reported. It is important to note that persistent cough
is becoming a major sign of AIDS overtaking weight loss and
chronic diarrhoea. Profound weight loss, chronic diarrhoea and
prolonged fevers were noted to mark major signs and symptoms
of AIDS in the pre-ARVs era (WHO 1987, (Piot et al. 1984). In
addition, pain in terms of headache, abdominal pain and burning
or burning/tingling sensations, when both symptoms are
considered across the pain trajectory becomes one of the most
frequently reported symptoms. Pain has been reported in other
settings as one of the most frequent symptoms (Bhengu et al.
2009), (Sukati et al. 2005). This finding suggests that pain
management must be prioritized by clinicians caring for HIV/
AIDS patients.
The number of children enrolled was rather lower than the 12%
program set target.  However, diagnosis and provision of ART in
HIV-infected children is more complex than in adults. Diagnosis
of exposed infants up to 18 months of age requires HIV-p24,
RNA or DNA polymerase chain reaction tests (Lyamuya et al.
1996). And also CD4+T cell percentage is required instead of
absolute CD4+T cell count for older children which were not
available during the study period. Therefore enrolment of children
was only based on clinical manifestation and HIV antibody
positive tests. This way many HIV-infected children might have
been missed. The ongoing implementation of early infant
diagnosis using DNA polymerase chain reaction and the family
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cantered program are expected to increase enrolment of children
into ART.
A great achievement was observed through the relatively high
percentages of patients received HIV-test at Outpatient unit,
Tuberculosis unit and some from the inpatient unit of the health
centre. These findings signify the implementation of provider-
initiated testing and counselling (PITC) a complement to VCT.
PITC was initiated with the aim of increasing uptake of HIV
testing, improve access to health services for people living with
HIV, and create new opportunities for HIV prevention at the time
when Chalinze town had only one stand alone VCT centre. PITC
is implemented using the Opt-out approach (WHO 2007)
involving the health care provider specifically recommending an
HIV-test to patients attended at any of the health centres’ units.
Then pre-test information is provided, followed by HIV test
performed in the usual way unless the patient declines to be
tested.
Many studies have recorded high mortality rates in the first three
months in patients who were initiated on ART with CD4<200/µl
(Jerene et al. 2006). In contrast none of the patients on ART
died during the study period, despite of the majority started ART
with CD4<200/µl. The possible explanation on the lack of early
mortality can be due to the lower prevalence of severe anaemia
in this population (mean haemoglobin 10.9 in ART patients).
Severe anaemia (Haemoglobin <8g/dl) is known to be correlated
with high mortality rates in AIDS patients (Langford et al. 2007).
In this study setting WHO clinical staging was expected to be
used more frequently than CD4+T cell count in deciding ART
initiation. However, due to unsatisfactory history taking and
physical examination practices, clinicians had to wait for CD4+T
cell counts results and delayed to initiate patients on ART. Such
delays might have contributed to the deaths of patients on care.
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Papular Pruritic eruptions (PPE) were the most frequently
diagnosed AIDS defining illness in this population. Dermatological
manifestations remain a major issue for those living with HIV
disease because skin manifestations are often disfiguring and
stigmatizing. The characteristic of skin problems in HIV-infected
individuals clearly indicates immunosuppression and have
accompanied AIDS from early days of the epidemic (Piot et al.
1984), (WHO 1987). PPE is a cutaneous marker of advanced
HIV-infection and is known to be uncommon in immune-
competent persons (Resneck Jr et al. 2004), (Eisman 2006).
Kaposi’s sarcoma and Herpes zoster are companions of skin
problems in AIDS patients. Although, these disease conditions
occur in low frequencies but are always present in HIV-patient
cohorts and are associated with severe immunodeficiency
(Goedert et al. 1998). Early detection and treatment have been
associated with long term survival of patients (Eisman 2006).
Thus strategies aimed at active case finding of Kaposi’s sarcoma
and PPE need to be developed and clinicians should be alert in
assessment and initiation of interventions for these problems.
Tuberculosis remains common ADIs in HIV and AIDS patients,
and is an early Opportunistic disease in the course of HIV-
infection which carries the highest case fatality rate (Dye et al.
1999) (Corbett et al. 2003).  At Chalinze health centre
Tuberculosis diagnosis rely entirely on clinical suspicion and
sputum examination, but still more than 30% of ADIs cases were
due to Tuberculosis. This finding indicates that more tuberculosis
cases can be diagnosed in this population if standardized
Tuberculosis screening tools and chest x-ray examination are
added to the sputum microscopy examination. Intensified case
detection and contact tracing need to be instituted in tandem
with community based prevention measures.
The potential limitations of this study include the fact that patients
were not interviewed to solicit their views on the quality of care
provided.
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Despite of the aforementioned limitation, we have highlighted
important findings which provide confidence to program
managers and clinicians that health centres can provide ART
services. In addition Health centre based ART services improves
access to many HIV/AIDS patients in rural areas.
In conclusion, the successes and the weaknesses indicated by
this study are the lessons learned and are essential references
in the course of HIV/AIDS scaling-up process in rural Health
centres. Proper linkage and referral network of health centre
ART clinics with nearby diagnostic facilities is essential to ensure
quality health care in rural settings. Supportive supervision and
clinical mentorship could be established simultaneously with the
initiation of ART services in health centres.
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Table 8. 2: Characteristics of HIV patients enrolled for ART
services between May 2007 and June 2009 at Chalinze Health
Centre
Characteristics All 
patients  
(N=895) 
CARE  patients 
(N=611) 
ART-patients 
(N=284)
Age group (years) n (%)    
 )3.21( 53 )0.61( 89 )8.41(331 42
 )8.23(39 )7.43( 212 )1.43(503 43-52 
 )8.73(701 )0.43( 802 )2.53(513 54-53
 )2.71(94 )2.51( 39 )8.51(241 54>
Sex   n (%)                      
Female                    622(69.5) 433(70.8) 189(66.4) 
 )6.33(59 )2.92( 871 )5.03(372 elaM
Weight, mean(SD) kg     
Female                    46.3(1.5) 49.2(1.2) 43.6 (1.5) 
 )8.1( 1.54 )3.1(4.15 )5.4(3.35 elaM
Functional status n (%)    
 )9.36(181 )4.96(424 )6.76(506 gnikroW
 )2.33( 49 )6.03(781 )4.13(182 yrotalubmA
CD4+T Lymphocytes    
 )6.97(622 )1.35(423 )5.16(055 lµ/053
 )4.02( 85 )9.64( 782 )5.83(543 lµ/053>
WHO clinical stage    
 )7.52(37 )6.74(192 )7.04(463 II &I
 )3.47(112 )4.25(023 )3.95(135 VI &III
    
Hemoglobin, mean(SD) 10.9(2.8) 10.8 (2.7) 10.9 (2.9) 
Mortality rate per100 patient-
years (95%CI) 
2.13  (1.31-3.48) 0.04 (0.01-1.01) 
_<
_<
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Table 8. 3: Clinical manifestations by CD4+T-Lymphocyte
counts of 895 patients with HIV and AIDS attended between
May 2007 and June 2009 at Chalinze Health Centre
Clinical feature CD4+T-Lymphocytes counts 
<100(N=361) 100-
200(N=227) 
>200(N=307) P value 
N (%) N (%) N (%)  
Weight loss 155(42.9) 63(27.9) 74(24.1) <0.001 
Skin itching/rashes 114(31.5) 59(25.8) 58(18.8) 0.001 
Fever 107(29.6) 45(19.9) 58(18.8) 0.002 
Body weakness 101(28.0) 41(18.2) 42(13.8) <0.001 
Productive cough 93(25.8) 34(14.8) 45(14.8) <0.001 
Headache 75(20.7) 29(12.6) 29(9.6) <0.001 
Numbness 69(19.0) 39(17.1) 43(14.1) 0.212 
Nausea and vomiting 40(11.1) 13(5.7) 14(4.7) 0.003 
Dry cough 43(11.8) 26(11.3) 23(7.5) 0.137 
Parotid enlargement 37(10.2) 22(9.9) 22(7.3) 0.356 
Chronic diarrhoea 28(7.8) 9(3.8) 10(3.4) 0.021 
Dysphagia 25(7.0) 6(2.8) 13(4.2) 0.052 
Abdominal pain 68(18.9) 23(10.2) 14(4.7) <0.001 
Oral Candidiasis 61(16.9) 16(6.9) 16(5.1) <0.001 
Pallor 42(11.7) 6(2.8) 10(3.2) <0.001 
Dermatitis 19(5.3) 10(4.4) 7(2.2) 0.139 
Genital discharge 17(4.6) 6(2.8) 5(1.7) 0.066 
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Figure 8.2 : Cumulative number of patients enrolled, started ARV, still on
ARV and retention status during the study period (May 2007 – June 2009)
Figure 8.3: Place of HIV test for patients enrolled for HIV care and treatment at
Chalinze Health Centre, Tanzania
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Figure 8.4: Methods used to evaluate patients eligibility to start ART at Chalinze
Health Centre, Tanzania
Figure 8.5: AIDS-defining illnesses treated between May 2007 and June 2009
at Chalinze Health Centre, Tanzania (n=282)
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Part IV
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Chapter 9: Discussion, conclusions and recommendations
Management of HIV and AIDS cases remains a challenge for
health care workers and program implementers due to
heterogeneity of clinical manifestations, concurrent infections and
co-morbidity caused by endemic diseases. Over the past
decades, management of HIV and AIDS has advanced in various
fields ranging from development and testing of pre-ARVs
resistance markers in HIV-drug naïve patients, CD4+ T
lymphocytes monitoring to the use of fixed dose ARVs
combination therapy. Nevertheless, HIV and AIDS continue to
be one of the leading causes of morbidity and mortality in SSA
(1). Finding effective HIV cure remains the greatest hope for
PLHA.
Under the current circumstances and on the absence of an
effective cure provision of optimum HIV care and treatment is
the only option to prolong lives of PLHA and prevent further HIV
infection. More important ART is becoming available in the
peripheral (rural) settings where access to heal th services and
proper medication is limited. In these settings, until recently HIV
related deaths were common due to poor access to ART (2).
Gradually, rural residents have started to experience benefits of
ART after the establishment of care and treatment services at
some health centres.
In poor resourced countries the public health sector have
recorded remarkable benefits in patients’ survival outcomes due
to availability of free ART compared to the period without ART
(3). Despite of these achievements higher mortality rates in the
first 6 months of ART compared to developed countries has raised
concerns. It is possible that early higher mortality is caused by
co-infections that lead to continuous co-morbidity coupled with
late presentation to care and treatment. The high burden of
Opportunistic infections and polyparasitism in poor tropical
populations profoundly affects the outcome of HIV/AIDS (4).  Co-
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infections with unrelated parasites increase the parasites overall
virulence and adversely affects the natural history and
progression of HIV/AIDS. It has become increasingly clear that
HIV/AIDS, tuberculosis, and malaria occur predominantly in
populations who are poly-parasitized. Helminths are the most
common parasites found in HIV-1, tuberculosis, and malaria
infected populations. Almost all of the major tropical diseases
have been linked with HIV/AIDS, tuberculosis, and malaria.
Several studies point to the increasing risk and severity of clinical
malaria that result from helminths co-infection and or
Schistosome infections in HIV-1. In Malawi, a study showed that
women infected with hookworms were at 1.8 more times higher
risk of having malaria than uninfected women (5). Gallagher et
al. 2004 observed increased risk of mother-to-child HIV
transmission in pregnant women with helminths co-infection (6).
In addition, there is some evidence that helminths infections
adversely affect the outcome of pulmonary tuberculosis or the
progression to active tuberculosis in HIV-1 infected persons.
Taken together, this evidence indicates that co-infection with one
or more parasites or Opportunistic infections may profoundly
affect the outcome of HIV/AIDS, tuberculosis, and malaria.
We are still in the early stages of appreciating the full extent of
the co-morbidity that occurs when helminths are superimposed
on HIV/AIDS, tuberculosis, and malaria. Anaemia has been
revealed as perhaps the most important of the leading co-
morbidity conditions. HIV/AIDS, tuberculosis, helminths and
malaria infections results in Anaemia, with malaria responsible
for the greatest burden. Severe Anaemia resulting from helminths
poly-parasitism and malaria produces several adverse health
consequences among the three particularly important African
subpopulations: pregnant women, children, and individuals with
HIV-1 infection. Among individuals with HIV-1 infection, Anaemia
has been shown to be an independent risk factor for early death;
correction of Anaemia results on decreased risk.
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Evidence of the extensive geographic overlap between HIV-1
infection and tropical diseases, together with the deleterious
interactions between both groups of infections, suggests
significant, new opportunities to reduce the burden of disease in
sub-Saharan Africa. HIV/AIDS, tuberculosis, and malaria
programs should therefore expand their portfolios to integrate
helminths and other neglected tropical disease control to reduce
morbidity and mortality in vulnerable populations.
Our study identified about 30% of HIV-infected patients who could
not be clinically staged appropriate according to WHO clinical
stages, because they lacked the required signs and symptoms
required in the guidelines. Some of these patients were found to
have CD4+Tcells<200/µl the critical cutoff point below which
serious Opportunistic infections occurs. Despite the recent
change in criteria for ART initiation in resource limited settings
from the previous CD4+Tcells<200/µl to CD4+Tcellsd” 350/µl (7),
the challenge of access to CD4 count remains unresolved in
peripheral (rural) HIV/AIDS clinics. Clinicians caring for HIV and
AIDS patients in the peripheral (rural) are not able to decide on
the appropriate management for some patients. Although the
WHO clinical criteria continues to be emphasized as the basis
for deciding initiation of ART, patients presenting with clinical
stages 1 and 2 can easily be regarded as early presenters due
to increased awareness of ART benefits and availability rather
than an outcome of a changed manifestation of a severe disease
which requires further laboratory investigations, which remains
un accessible. Patients with Herpes zoster and Papular Pruritic
eruptions which are clinical stage 2 conditions were found to
have CD4+Tcells<200/µl. Again, promotion of CD4 testing to all
patients is a practical approach which is not absolutely feasible
in peripheral (rural) settings where blood samples need to be
transported for CD4 testing. However, cohort specific clinical
manifestation profiles linked to CD4 count levels can complement
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decision on when to start ART in patients with symptoms not in
fitting with WHO clinical staging listed conditions.
Clinical staging is intended to guide decisions on when to start
ART and when to start cotrimoxazole prophylaxis. HIV/AIDS
treatment guidelines provide details of specific staging conditions
and criteria for recognizing them. Clinicians need to understand
and know how to apply these criteria to individual patients.
However, our findings at Chalinze health centre cast doubt on
the ability of some clinicians to appropriately clinically stage
patients. The brief clinical consultations which were not long
enough to register complete history and clinical examination
raises questions on quality of case management in similar
settings. Thus CD4+Tcells count results become an important
factor to appropriately manage the patient and avoid delaying
ART to patients in need. Introduction of job aids and simplified
protocols based on local experiences can improve the overall
performance of clinicians and better care of HIV/AIDS patients.
Most patients who reported at the clinics during the study period
(April 2008 to March 2009) had severe immunosuppression this
is indicated by their low median CD4 cell count at presentation
(84 cells/µl (IQR 29-127)). This can be explained by late
presentation at the beginning of the program a characteristic of
most HIV/AIDS programs in SSA. It is expected that as ART
services continue to be widely accessible, patients will start to
present early to HIV-clinics and reduce losses to follow-up.
Several other reasons explain why patients are lost to follow up
and present late to clinics. Availability of alternative care provided
by local traditional healers partly contribute to treatment delaying
patients to seek modern health care, no-adherent and dropout
of patients from care (8). It is a common experience in resource
poor settings of Africa for HIV-patients to consult traditional
healers for psychosocial and health care first before moving to
hospital and or other patients move away from hospitals to
tradition healers. Collaboration and integration of traditional
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healers in HIV and AIDS care programs have benefited patients
and the program in some settings of East Africa (9). We
recommend establishment of collaboration between traditional
healers and HIV program in areas where the two services exist.
Traditional healers need training to understand basic HIV/AIDS
information including availability and benefits ART. They should
be encouraged to refer patients to hospitals and avoid
concomitant administration of herbal medicines and ART.
Main findings and their implications for future research and
interventions
This study covered four important issues as outlined in the goal
and objectives. These findings provide useful considerations in
the process of scaling-up and provision of ART in peripheral (rural)
or semi-urban settings with limited resources.
With respect to the first objective, the study documented and
analyzed HIV and AIDS clinical manifestations and CD4+T
lymphocytes count, examined the sensitivity of each symptom
or sign to predict CD4+T lymphocytes count d”350 /µl. One key
finding is that by combining three symptoms including diarrhoea
which persisted for more than two weeks in a HIV-positive
individual is a good predictor of CD4+T lymphocytes count d”350
/µl. Considering this finding and the fact that more than 50% of
the patients present to HIV and AIDS clinics with CD4+T
lymphocytes count d”200/µl, this has significant consequences
not only on mortality as described in other studies, but also in
the approach to case management. In settings where CD4+T
lymphocytes counts are not readily available, local experiences
of prevalence and types of symptoms presented by those living
with HIV/AIDS should be used to initiate ART. Operation research
to document cohort specific HIV clinical presentation correlated
to CD4 count levels should be undertaken in all clinics with large
numbers of patients.
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Some signs and symptoms experienced by HIV and AIDS
patients occur across the trajectory of HIV-disease did not
efficiently predict CD4+T lymphocytes decline. Such
manifestations include: headache, fatigue, abdominal pain and
peripheral neuropathy. These symptoms were found relatively
weak in predicting severe immunosuppression. It is also important
to note however that such symptoms may occur secondary to
traditional herbal medications taken by patients prior to enrolment
to HIV-clinic and can influence the relationship between
symptoms presented and CD4+T lymphocytes changes (10).
Each symptom experienced by HIV and AIDS patients influences
on the patient’s quality of life. Persistent headache is bothersome
and may signify an underlying serious systemic condition or co-
medications. Skin lesions cause disfiguring and at times serious
discomfort due to itching, as a result self stigma, isolation and
depression. However, most of these symptoms can be controlled
by using ART if initiated during the early stages of AIDS.
HIV clinical manifestations most often mimic clinical symptoms
and signs of endemic diseases common in a particular region
(11). Bacterial infections including tuberculosis in HIV-infected
individuals have been well studied because of their public health
importance in most regions of the world (12). Parasites co-
infection in HIV/AIDS on the other hand, have currently been
given due attention, especially intestinal helminths which present
without specific signs and symptoms. However, further research
on the role of helminths and other endemic parasites comorbidity
in addition to HIV disease and the impact of comorbidity on overall
HIV and AIDS case management should also be explored.
With regard to the second part of the first objective, the study
investigated the interaction between parasites and HIV in terms
of effects on CD4+T lymphocytes and clinical monitoring of HIV/
AIDS patients. Current clinical practice in HIV/AIDS clinics do
not routinely screen for parasites co-infection in HIV-patients.
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Such practices allow underlying morbidity caused by parasites
to advance and complicate clinical outcome.
Findings of this study suggest that there is a high prevalence
rate of malaria and intestinal worms in HIV/AIDS patients. This
should form the bases for cohort specific studies to determine
the burden of parasites co-infection in HIV/AIDS patients and
choose the appropriate modality of care.  Similarly, HIV/AIDS
clinics should be seen as opportunity for implementing
intervention studies to address the problem of co-infection and
co-morbidity. Study results show the benefits of treating parasites
at the time of initiating ART through improved CD4+T
lymphocytes counts recovery equivalent to that of patients without
parasites co-infection. It can be argued that if HIV/AIDS programs
can implement mass treatment for endemic parasites at care
and treatment clinics, recurrent morbidity and probably mortality
can be further reduced. It is important, therefore, to conduct
research to establish local burden of parasites in HIV-infected
patients’ cohorts in order to guide interventions.
The second objective of this study examined factors related of
non-adherence to combination ART. Optimal ART adherence is
essential for maximal suppression of viral replication and long
term survival of patients. Different settings have specific barriers
that influence adherence to ART; such barriers are not necessarily
shared by populations in other settings. This study identified two
behavioural factors: disclosure status and alcohol drinking as
strong predictors of non adherence to ART. Other non-
behavioural factors were inadequate knowledge of basic
prevention methods; poor adherence to clinic appointments
(because of lack of money for transport) and unsatisfactory with
providers. Study findings clarify the dynamic nature of adherence
to ART and its dependence on setting-specific influencing factors.
Adherence improvement strategies need to take into
consideration site specific determinants, patient experiences and
concerns. It is even more complex to maintain adequate
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adherence in rural areas due to seasonality of economic activities
and consequential seasonal household mobility especially in
settings where farms are located far away from homes and in
transhumance nomadic populations (13).
There are several strategic options for Tanzania National AIDS
Control Program to consider implementing or adopting for
peripheral (rural) population. In the case of seasonal or
transhumance population migrants to farm lands quarterly mobile
ART clinics to selected farm sites could provide an opportunity
to maintain adherence to ART. For non mobile population,
patients residing far from the HIV/AIDS clinic quarterly ARVs
prescriptions and or drug refills collected by a treatment assistant
can reduce transport costs and encourage adherence success.
Nevertheless, research is needed on ART adherence and
virological suppression in patients receiving three monthly ARVs
supplies. The Tanzania National AIDS Control Program in
collaboration with district ART teams need to identify mobile
populations and establish community-directed outreach ART
clinical teams. Such teams can be deployed in a regular basis to
sites far from ART clinics. This strategy will ensure continued
access to ART and improve adherence for patients in mobile
population. For peripheral (rural) hard to reach population
establishing ART refill stations within the community could be
considered and will benefit inhabitants of these areas.
HIV/AIDS care and treatment clinic provides an opportunity to
deliver prevention messages and interventions to patients.
Usually patients establish trusted relationship with health care
providers and hence are more likely to listen, accept and practice
prevention methods provided by health care workers. The study
finding show that patient with inadequate knowledge of basic
prevention methods were more likely to be non-adherent to ART.
This finding is striking and can be extrapolated to the deficiency
in contents of health talks. Health talks are useful in terms of
HIV-infection control if delivered properly and contain relevant
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information. AIDS prevention messages constitute part of post
HIV-test counselling and continuous health education delivered
to patients during routine consultations. It was therefore expected
that patients would be knowledgeable of prevention messages
but there was no compelling evidence found.
The quality of provider-patient interaction is an important factor
in determining patient satisfaction with the services provided,
and responsible for poor access to services. Stress of the work
environment creates a negative impact on the provider behaviour.
Sometimes health providers become irritable and handle patients
in the wrong way because of infrastructure problems (patient
overcrowding, lack of electricity and inadequate water supply).
Overwork due to staff shortages which lead to performing of
multiple tasks; and shortages of drugs and supplies (14)
negatively impact on provider-patient relationship.  The use of
non-professional staff to perform some activities which do not
require much of a medical knowledge (15), optimizes skills of
the health worker to cope with growing patient loads. Regular
supportive supervision, opportunities for professional and career
development, and recognition of staff performance boost staff
morale, and job satisfaction (16).
The third objective of this study focused on experiences and
lessons learned in the process of providing ART in peripheral
(rural) health centre. The process of scaling-up ART is seen as
a comprehensive and equitable strategy to stem the burden of
HIV/AIDS in poor rural settings. However, the use of ART in poor
settings has been challenged mainly due to lack of adequate
infrastructure and the related medication costs (17). These issues
have been continuously addressed by the International
community, but the widespread use of ART raises the issue of
lack of experience and best model of care to be replicated in
similar settings.
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The following lessons derived from managing HIV and AIDS at
the Chalinze health centre ART services outcomes to date and
the possibility of replication of similar achievements to other
settings, the following aspects stand out: (1) ART services can
be provided effectively at a Health centre by less trained medical
staff after a two weeks training course in HIV and AIDS care and
treatment. (2) Proximity of ART services encourages entry and
retention in care for patients who initially could not afford regular
travelling to access care and treatment services. (3) Providing
ART services at Health centre strengthens the primary health
care system and it also provides the opportunity to benefit none
HIV health care services in terms of infrastructure improvement,
improved laboratory diagnostics and strengthened referral
networks.
The concept of integrated HIV/AIDS care and treatment as
pioneered in Tanzania by the St.Francis Designated District
Hospital chronic disease clinic (18) has benefits beyond improving
health care system. At Chalinze health centre, the integrated
nature of ART services gives an opportunity to patients to receive
all appropriate essential services in a coordinated way. The
dramatic physical wellbeing of AIDS patients who were at a
terminal stage and reduction in morbidity as a result of ART intake
increased confidence in clinical care. As result, the multi-purpose
structure of health centres services creates an environment that
enables HIV/AIDS patients to be accepted by their communities
where they live. Under this clinical arrangement, the role of ART
in reducing stigma and discrimination for PLHA can be realized.
Furthermore, HIV and AIDS require multi-drug therapy over an
extended period of time so providing ART at health centres close
to majority of the poor patients promises good treatment
adherence and reduction of risk factors for development of drug
resistance (19)]. Under these circumstances and the benefits
observed, it is possible to provide ART safely and effectively in a
resource poor setting.
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Recommendations
The findings of this study provide useful recommendations for
HIV/AIDS program, health system and the community.
HIV/AIDS program level
(i)  Introduction of additional screening tools for pneumonia and
Kaposi’s sarcoma
Pneumonia and Kaposi’s sarcoma requires x-rays and skin
biopsy for diagnosis confirmation, respectively. The lack of
these diagnostic technologies in rural health facilities results
in missed diagnosis and occasionally suspected cases of
these conditions receives referral at patients’ own transport
costs. Many patients in this study presented with chronic
cough and fever, while the number of patients diagnosed
with pneumonia was too low compared to the number of
cough cases attended. Similarly Kaposi’s sarcoma lesions
can be easily missed by clinicians during clinical examination,
especially lesions in the mouth and other body cavities.
Development of symptom and signs based screening tools
similar to the one used for screening tuberculosis will increase
case detection and provision of appropriate management.
Additionally, symptom and signs checklist tools if used
properly are likely to improve the quality of HIV-case
management in peripheral (rural) health centres.
(ii) Integrated supportive supervision
The goal of supportive supervision is to promote effective,
efficient and equitable health care.
Providers in health centres require regular supervision from
supervisors who can provide clear guidance and sufficient
information aimed at improving patient management
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procedures, provider-patient interactions and overall
management of primary health care facilities.
HIV and AIDS programs need to develop an intervention
package containing all components of ART services. The
intervention package will then be used by Regional health
managers during routine supervision.
(iii) Clinical mentorship program
Periodic mentorship program for clinical staff need to be
instituted to enhance the knowledge and clinical decision
making skills of clinicians providing care to HIV and AIDS
patients. A multi disciplinary team of trainers drawn from the
region health management team equipped with skills to
provide one-on-one and small group case based training
need to be established. Such an intervention will improve
the quality of HIV case management and clinical outcomes.
Health care delivery system level
(i) Task shifting
Task shifting must be seen as part of an overall strategy that
includes tangible measures to increase, retain and sustain
existing and new cadres of staff. Existing staff need to be
flexible, motivated and support the delegation of some of their
duties in order to cope with the increasing burden of HIV/
AIDS. Examples of tasks which can be lay-health care at a
health centre level include: provision of basic HIV support,
treatment adherence and psychosocial support; record clerks
filling in basic patient information and measuring body weight.
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(ii) Staff shortages
Addressing staff shortages through expanded training
opportunities and incentives to attract health care workers to
remain and or accept to move and work in peripheral (rural)
health centres is an important step towards ensuring quality
health services. The use of retired health care workers to
provide less demanding services like antenatal care and
vaccination should be encouraged to alleviate work load to
existing staff.
(iii) Laboratory diagnosis
Strengthening laboratory infrastructure at health centres
requires the provision of basic equipments and training of
technicians to improve their knowledge and skills and provide
quality results. Basic laboratory tests that are essential for
routine care like stool examination for helminths, urine,
sputum, haemoglobin and blood slides need to be improved
at the Regional hospital and health centres. This should be
carried out in tandem with the establishment of quality
assurance systems and refresher training of laboratory
technicians. Sample transportation from health centre to
regional laboratories for CD4 cells count analysis, results
turnaround time and reliability of the results need
improvement. Coordination and communication between
laboratories, clinic units and patients, equipment
maintenance and referral processes should be established.
(iv) Routine screening of helminths in stool and urine; and malaria
parasites in blood. Patients registering for the first time at
care and treatment clinics should be screened for parasites
prevalent in the area. Tanzania National AIDS Control
Program need to incorporate parasites screening and
treatment in the HIV/AIDS case management guidelines and
treatment packages.
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(v) Changing HIV/AIDS clinical presentation
Tanzania National AIDS Control Program in collaboration
with clinics managing large HIV/AIDS cohorts need to
regularly review HIV/AIDS clinical presentation and their utility
in WHO clinical staging. This approach will assist clinicians
in peripheral (Rural) settings to improve patient management
and reduce possibility of inappropriate clinical staging. In
addition data will readily available for revision of National
treatment guidelines.
(vi) Availability of simpler CD4+T lymphocytes counts
Development of simpler CD4+T lymphocytes counts testing
tools which uses solar power and requires no electricity and
or refrigeration (cold chain).
HIV/AIDS patients’ management continues to be guided
primarily by clinical staging owing to the insufficient
availability (or frequent breakdowns) of CD4 cells count
machines, shortage of qualified medical staff and lack of
laboratory reagents due to logistic issues. CD4+T
lymphocytes count machines currently in use are very
complex and require highly qualified laboratory technicians
to operate. These equipments cannot be installed in
peripheral (rural) health centre with simple infrastructure and
unreliable electricity supply.
Given all these technical and logistic issues, we propose
the development of a simple and user friendly CD4+T
lymphocytes count instrument which can be used in
peripheral (rural) health facilities. The instrument should
mimic the pregnancy test or the HIV-antibody testing
instruments used in Voluntary Counselling and Testing. A
two compartment instrument with different colour coding for
each compartment categorized by the amount of CD4+T
lymphocytes concentration (CD4d” 350 cells/µl and
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CD4>350 cells/µl to provide useful information to guide HIV/
AIDS clinical care.
(vii) Improved (IEC) information
Although IEC materials are available in health facilities the
need to improve information contents of these materials to
cover patients’ needs and concerns is critical. Patients need
to be educated on ART benefits, adherence requirements
and eligibility to ART. The amount of information should be
reduced and simplified to enhance easy recall.
(viii) Poor quality of services provided
Quality of care is a concern in health care facilities (20)
and both technical and perceived quality of care needs to
be addressed through improved appropriateness of
diagnosis, prescribed treatment and interpersonal care
including proper advice. Intervention to improve quality of
care should consider addressing staff motivation,
improved counselling and patients’ follow-up.
(ix) Sub-optimal adherence to ART in  mobile  population
NACP and District HIV/AIDS programs collaboratively can
develop and implement adherence strategies to address
adherence problems affecting patients residing in mobile or
migratory populations.
Community level
i) Advocacy
Community based advocacy of the benefits of ART and early
clinical consultation after a HIV-test positive result is required
to reduce the number of late reporting and poor adherence to
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ART. In principle health intervention programs should
incorporate ART information with emphasis to access, benefits
and adherence requirements. This strategy will enhance early
and appropriate treatment seeking behaviour.
ii) ART refill stations
Geographic access to health facilities is relatively good in
Tanzania with approximately 75% of the population living
within 5 km of a health centre or dispensary (21). Since not
all health centres have the capacity to provide full range ART
services. However, they provide an important infrastructure
which could be used to improve access to ART in peripheral
(rural) areas by establishing ART refill stations. The dispensary
provides good infrastructure for storage of drugs and
monitoring of adherence to ART. Since the dispensary is within
walking distances for most of the people in peripheral (rural)
settings transport costs and waiting times is reduced.
Implications for future research
1. Case-control studies are needed in peripheral (rural) and
urban settings to determine factors contributing to delay
for seeking ART care after testing HIV-positive. This study
indicated substantial delay in seeking care following a HIV-
test positive result. The consequences of delayed initiation
of care and treatment are determinants to patient survival,
ART effectiveness and HIV-1 transmission.
2. Cohort studies are required to determine the levels of
adherence to ART and virological suppression for patients
receiving three months ART supplies. The comparison
group may be patients receiving routine monthly ART
supply.
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3. HIV/AIDS Cohort specific studies on the types and burden
of parasites and other important co-infections will be used
to guide development of site specific intervention
strategies and case management approaches.
4. Cross-sectional studies specific to a geographical area
and HIV/AIDS cohort are need to establish HIV/AIDS
patients’ cohort specific clinical manifestations. These
studies will provide evidence for continuous amendments
of care and treatment guidelines.
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